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Background 
HIV positive patients present a higher risk of cancer compared to the HIV-negative 
population. Three tumors, namely Kaposi sarcoma (KS), non-Hodgkin lymphoma 
(NHL) and invasive cervical cancer (ICC) occurs with particularly high incidence in 
HIV-positive patients, and have been classified as AIDS-defining malignancies 
(ADMs). 
However, a risk excess is observed for both ADMs and non-AIDS defining 
malignancies (NADMs). 
Co-infection with oncogenic virus occurs as a key pathogenic factor in ADMs 
(namely, Non-Hodgkin lymphoma (NHL), Kaposi sarcoma (KS), anal and cervical 
cancer) and in some NADMs (anal cancer, haepatocellular carcinoma (HCC) and 
Hodking lymphoma (HL). Beside co-infection with oncogenic virus, the pathogenic 
pathways underlying the development of infection-related and non infection-related 
cancer in people living with HIV (PLWH) are sustained by a  complex network of 
interactions between various components of the immune system, with cytokines 
and other pro-inflammatory agents mediating  those interactions. However, these 
mechanisms have not been fully characterized.  
 
Aim 
To shed light on this topic, we conducted 3 studies with the following aims:  
- Association of T-cells activation markers and CD4+/CD8+ ratio with virus 
related and non-virus related cancers in HIV-positive patients:  High levels of 
peripheral T-cells immune activation and low CD4+/CD8+ ratio in HIV-positive 
patients have been associated  with comorbidities and increased risk of 
serious events and deaths, despite effective combination antiretroviral 
therapy (cART). Thus, we aimed to assess the association of peripheral 
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immune activation markers (CD8+CD38+ T-lymphocytes) and CD4+/CD8+ ratio 
with the onset of infection-related and non-infection related cancers in a 
cohort of HIV-positive patients. We further investigated possible association 
of CD8+CD38+ T-cells and CD4+/CD8+ ratio with overall survival of HIV-
positive patients with virus-related cancer and non virus-related cancer.  
- Natural Killer cell populations in HIV associated lymphoma: Natural Killer (NK, 
CD56+) cells exert anti-cancer and anti-viral actions and their number and 
function is impaired during HIV infection. In HIV-negative patients with 
Hodgkin Lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL), NK cell 
constitute a higher percentage of circulating lymphocytes and are associated 
with a better outcome. We aimed to evaluate the NK cell population in HIV-
associated lymphomas. 
- Sex-based differences in factors associated with HPV infection and 
intraepithelial lesions in a cohort of HIV-positive patients: We aimed to assess 
the factors associated with Human Papilloma Virus (HPV) infection and with 
squamous intraepithelial lesions (SILs) in a cohort of HIV-positive patients with 
focus on gender differences, and possible factors linked with the capability to 
clear HPV infection, thus influencing the progression of  SILs towards cancer.  
 
Materials and methods 
For the following studies:  
- Association of T-cells activation markers and CD4/CD8 ratio with the onset of 
virus related and non-virus related cancers in HIV-positive patients; 
- Sex-based differences in factors associated with HPV infection and 
intraepithelial lesions in a cohort of HIV-positive patients; 
6 
 
we enrolled antiretroviral-naive and cART-treated HIV-infected patients in active 
follow up at the SPID (San Paolo Infectious Disease) Cohort. The SPID cohort was set 
up in 2006 and includes all HIV positive patients who are attending the outpatients 
service of Infectious Diseases’ Clinic at San Paolo Hospital, Milan, Italy.  
According to the study, patients underwent blood exams and gynaecological or 
surgical visits with colposcopy/anoscopy at baseline (time of first visit); a 
longitudinal study was performed on an unselected subgroup of patients who 
repeated the same evaluation after 12-24 months.  
Lymphocyte subsets were evaluated by flow cytometric analysis. 
For the study on Natural Killer (NK) cells in a cohort of HIV-positive patients, we 
enrolled patients who attended  at the National Centre for HIV malignancies at the 
Chelsea and Westminster Hospital, London, UK.  We included 615 HIV seropositive 
patients diagnosed with lymphoma between 1988 and 2017. Data on patient 
characteristics, prognostic factors, treatment and outcomes were extracted from 
the database.  
Lymphocyte subsets were evaluated by flow cytometric analysis.  
Comparison of variables between the groups was by Chi-squared test for categorical 
data and Kruskal-Wallis test for non-parametric continuous variables. The 
association between CD4+T-cells count and NK cells count was assessed by bivariate 
analysis. The time interval from lymphoma diagnosis until death, study censoring or 
loss to follow-up was used to calculate overall survival (OS). Survival curves were 
plotted according to the method of Kaplan and Meier. The log rank method was 
used to test for the significance of differences in survival distributions.  
 
Results 
Association of T-cells activation markers and e CD4/CD8 ratio with the onset of 
virus related and non-virus related cancer in HIV-positive patients:  we enrolled 
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140 HIV-positive patients, 115 with virus-related cancer and 25 with non-virus 
related cancers. Patients with virus-related cancer were younger (p<0.0001), with a 
shorter time from HIV-diagnosis (p=0.04), more frequently naïve to cART (p=0.009) 
and with lower CD4+CD8+ ratio (p=0.01) compared to patients with non virus-
related cancer. When we analyzed the group of patients on cART, CD4+/CD8+ ratio 
was comparable in infection-related and non infection-related cancer. Immune 
activation was similar in the two group. 
Neither CD4+/CD8+ ratio nor CD8+CD38+ were predictor of outcome in our cohort.  
Natural Killer cell populations in HIV associated lymphoma:  we  included in the 
analysis 360 lymphoma cases with full lymphocyte subset analysis at cancer 
diagnosis.  
 The percentage of natural killer (NK) cells was significantly higher in patients with 
Hodgkin lymphoma (HL) (median 9%) than in diffuse large B-cell lymphoma 
(DLBCL)(6%) and other non-Hodgkin lymphoma (NHL) subtypes (p=0.009). The total 
NK cell count was significantly higher in patients with undetectable HIV-
RNA(p<0.0001) but only weakly correlated with CD4 cell count (PearsonsR2 =0.11). 
For 156 patients with DLBCL, the 5-year OS was 64% (95%CI 56-72%) and in 
univariate analysis neither total NK-cell population (log rank p=0.14) not NK-cell % 
(log rank p=0.84) were prognostic variables for OS. In multivariate Cox model the 
only variable associated with OS was the International Prognostic Index (IPI) (log 
rank p<0.001). 
Sex-based differences in factors associated with HPV infection and intraepithelial 
lesions in a cohort of HIV-positive patients: 472 patients were enrolled.  
HPV infection(p<0.001), SIL (p<0.001), HPV persistence (p<0.001) and SIL 
progression (p=0.018) were all associated with male sex.  
Among females, HPV was associated with higher HIV-RNA (p=0.002)  and SIL was 
independently associated with lower CD4+ count (AOR: 0.998; 95%CI: 0.997-1). 
8 
 
In the males group, HPV was associated with homosexual intercourse  (AOR: 3.801, 
95% CI: 1.82-7.95) while AIDS diagnosis (AOR: 0.387 95% CI:0.176-0.851) and older 
HIV infection (AOR: 0.996 95% CI:0.992-0.999) were negatively associated with HPV 
infection; males with SIL were younger (AOR 0.973, 95% CI 0.95-0,997), more 
frequently men who have sex with men (MSM) (p=0.04) and with higher levels of 
immune-activation (CD38+CD8+%) (p=0.013) compared to SIL-negative males. 
 
Conclusions 
In our cohort, immune activation at the onset of cancer was similar in patients with 
infection and non infection-related malignancies. Patients with infection-related 
cancer had lower CD4+/CD8+ ratio, but this difference was no longer significant 
among patients on cART, supporting the importance of a prompt initiation of cART 
in restoring immune-deregulation in both virus and non-virus related malignancies.  
In this study,  CD8+CD38+ and CD4+/CD8+ ratio were not predictive of outcome in 
HIV-positive patients with cancer.  
When we analyzed HIV-positive patients with lymphoma of the National Centre for 
HIV malignancies at the Chelsea and Westminster Hospital, we found that NK cells 
deficiency is a key point in the development of non-Hodgkin lymphoma in PLWH and 
could explain, at least in part, the higher risk for malignancies that persists in the 
cART era. However, a lower NK cells count was not associated with a worse overall 
survival of our  patients with DLBCL, possibly because of a functional impairment 
beyond their quantitative depletion. Since in HIV-negative patients immunotherapy 
targeting NK cells is promising, further studies in people living with HIV (PLWH) may 
allow comprehending whether NK-cells antitumor function could be restored in 
these patients, and consequently exert their potential to boost the response to 
chemotherapy.  
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Finally, we found that despite an adequate immune recovery, HPV infection and 
clearance as well as the presence of intraepithelial lesions is largely influenced by 
risky behaviors and persistent immune activation in males, particularly in recently 
HIV-infected patients. Among women, on the other hand, the risk of precancerous 
lesions is linked to immune-suppression as measured by CD4+T-cells count; we 
suggest that these groups of patients should be considered for more accurate 
screening and extensive vaccination.  
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Epidemiologic features of oncologic disease in HIV-positive patients 
 
Since the beginning of the HIV pandemic, people living with HIV (PLWH) have been 
at higher risk of cancer compared to the general population. To date, cancer is 
responsible of one third of all deaths in HIV-positive patients1.  
          Three cancer types, namely Kaposi’s sarcoma (KS), non-Hodgkin lymphoma (NHL) 
and invasive cervical cancer (ICC) have been found to be associated with a 
particularly high frequency with AIDS, and therefore have classically been referred 
to as AIDS-defining-malignancies (ADMs) 2.   
          During 1990-1995, before the introduction of combination antiretroviral therapy 
(cART), the risk of KS, NHL and ICC in PLW was respectively 2800-fold, 10-fold and 3-
fold higher than the risk in the general population3.  
           After the advent cART in 1996 the incidence rate of ADMs has decreased, and this 
trend has been driven mostly by the sharp reduction in the incidence of KS and 
NHL4, while the incidence of ICC has not significantly been affected by the advent of 
cART5. However, KS is still one of the most common cancers in Africa and is globally 
the most common tumor in HIV-infected individuals6, while NHL still constitute 
>50% of all ADMs in developed countries7.  
           PLWH also show a higher frequency of non-AIDS defining malignancies (NADMs) 
and with the advent of cART, leading to a prolonged life expectancy in HIV-positive 
patients, the burden of NADMs has collectively over passed the burden of ADMs8 4. 
The relative risk of cancer in PLWH is particularly high for cancer with a known or 
suspected viral origin, with the notable exception of lung cancer and other smoke-
related cancer9.  
           Indeed, among NADMs the most prevalent is lung cancer, with a risk that is nearly 
three times higher in the HIV-infected than in the HIV-negative population10.             
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           A 2.1-fold higher risk of non-melanoma skin cancer and 1.8-fold higher risk of 
melanoma have been reported in PLWH compared to the general population11 12 13.  
Of note, breast cancer has a similar incidence in HIV-positive and HIV-negative 
women14 15.  The incidence of prostatic and colorectal cancer is also similar in HIV-
positive compared to HIV-negative individuals9.            
 
Among non AIDS-defining virus-related cancers, Human Papilloma Virus (HPV)-
related anal cancer is particularly frequent in PLWH and specially among men who 
have sex with men (MSM), who are likely to acquire HPV infection during sexual 
intercourse, with a 30 to 100-fold higher incidence rate compared to the general 
population16 17. Moreover, the risk for hepatocellular carcinoma (HCC) is 4-fold 
higher in PLWH than the general population. In a large retrospective cohort study on 
US veterans, HIV/HCV positive patients showed a higher risk to develop HCC than 
HIV negative ones18. The incidence of HCC has steadily increased among individuals 
with AIDS in the United States over the past 3 decades, and the relative risk excess 
for this kind of cancer has remained relatively unchanged over time, including in the 
cART era. 
Further, the risk of Hodgkin lymphoma (HL) has been shown to be 5 to 20-fold 
higher in PLWH than in the general population, with a similar incidence in the pre- 
and post-cART era19.  
 
            
          
Risk factors and pathogenetic aspects 
 
Non virus-related cancers 
14 
 
The reasons of the cancer risk excess in PLWH have not been fully clarified.  This can 
be in part explained with the high prevalence of classical cancer risk factors, 
primarily tobacco use, earlier smoking initiation and increasing proportion of HIV-
positive patients aged 50 yrs or older.  
A meta-analysis of 113 studies across developed countries, largely in North America 
and Western Europe, showed that 54% of HIV-infected people were current 
smokers20. A population-based survey of HIV-infected people in care in the United 
States during 2009 found that 42% were current smokers and another 20% were 
former smokers21. Another study reported the prevalence of smoking among all 
participants of the Swiss HIV Cohort Study to be 72%, and as high as 96% among 
injection drug users in the cohort11.  
As regard to the other risk factors for cancer development, a large meta-analysis 
found hazardous alcohol consumption prevalence not to be higher in PLWH 
compared to uninfected comparison group20. In the same report, the prevalence of 
obesity and overweight was higher in uninfected patients compared to PLWH.  
However, the elevation in  cancer incidence  appears higher than can be explained 
by smoking and other classical risk factors alone; immune suppression caused by HIV 
infection may be determinant, as supported by evidence for an increase in lung 
cancer risk with advancing time relative to AIDS diagnosis, and among transplant 
recipients22. Inflammation and immune senescence caused by HIV-replication could 
contribute to cancer risk23 2,  as well as pro-oncogenic effects of secreted HIV-
encoded proteins23. Specifically, HIV infection is associated with genetic instability, 
as suggested by the higher prevalence of microsatellite alteration in HIV-related 
than in non HIV-related lung cancers. Further, the action of some carcinogen factors 
may be enhanced in HIV-positive patients, due to the endothelial damage occurring 
during chronic infection, which could led to a permissive environment for cancer 
growth24.  
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Further, the more rapid immunologic aging in PLWH, which is characterized by a 
higher prevalence of CD8+CD28- , CD4+CD28-  cells, reduction in the number of 
CD4+CD31+ naïve T-cells,  shortened telomeres and increased CD56+CD57+ 
compared to age-matched HIV-negative patients25, could lead to an increased risk of 
cancer.  
 
 
Virus-related cancers 
Non Hodgkin lymphoma 
Role of HIV infection: Some of the more common types of systemic NHL occur in the 
setting of chronic B cell activation, and the effects of chronic B cell activation on 
lymphomagenesis are numerous, including the accumulation of oncogene mutations 
and translocations. 
HIV infection and consequent immune suppression contributes to oncogenesis 
through the loss of T-cells control over B-cells function; the subsequent B cells 
hyperactivation promotes the development of AIDS-NHL through the loss of 
immunoregulatory control over Epstein-Barr virus (EBV) -infected B cells; further, 
chronic hyperactivation and pro- inflammatory state promote the proliferation of 
dysregulated B cells26. 
It has further been proposed that HIV-infected macrophages could drive stimulatory 
signals that contribute to create a permissive microenvironment for malignant B-cell 
growth27. 
Role of coinfection with oncogenic virus: alongside the role HIV-infection per se, 
two gamma herpes viruses, Human Herpesvirus-8 (HHV-8) and EBV, have been 
shown to play a crucial role in the pathogenesis of a wide range of lymphomas. HHV-
8  is involved in the pathogenesis of primary effusion lymphoma (PEL) and large B 
cells lymphomas arising in patients with multicentric Castleman’s disease, whereas 
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EBV serves as a co-factor in the development of Burkitt lymphoma (BL), Hodgkin 
lymphoma and diffuse large B-cell lymphoma28. 
Viruses act by directly promoting oncogenesis via the action of viral proteins that 
regulates cells growth, survival and differentiation.  
Further, viral infection and persistence promote a dysregulation in the immune 
pathways of the host which is crucial in the development of NHL.   
Role of Natural Killer cells: Natural Killer cells (NK)  are a key component of tumor 
immune surveillance and play an important role in rituximab-dependent killing of 
lymphoma29 30. 
NK cells have a high cytotoxic potential and secrete a variety of cytokines and 
chemokines, such as γ-interferon (IFN- γ), that amplify the recruitment and 
activation of other participants to the antitumor response.  
NK cells are grouped  in two different subpopulations, namely CD56dim and 
CD56bright cells, based on the relative surface density of CD56 antigen31.  
The subset of  CD56dim NK have a high, CD16-dependent, cytotoxic activity, while  
CD56bright NK are potent producers of immuno-regulatory cytokines, and bear low 
or absent CD16. 
A recent study32 report baseline and long-term analysis of the phenotypic and 
functional dynamics of peripheral blood NK cell subsets in DLBCL HIV-negative 
patients, revealing tumor associated as well as therapy dependent alterations of the 
systemic NK cell compartment. 
Role of pro-inflammatory cytokines: a significant associations has been reported 
between elevated levels of B cell activation biomarkers and subsequent risk of NHL, 
including numerous cytokines, chemokines and soluble receptors. 
Interleukin 6 (IL-6) is a pro-inflammatory cytokine that has been recognized to play a 
role in promoting tumor growth, and has been found to be elevated in the serum of 
HIV-positive patients years before the development of NHL27. 
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Interleukin 10 (IL-10) is a potent B cell-stimulatory factor and strongly related with 
NHL risk33. 
A number of groups have evaluated serum biomarkers in an effort to more fully 
characterize the cytokine signaling underlying the immunological mechanisms 
involved in the development of AIDS-related NHL, focusing on some cytokines (IL-6), 
serum free light chains (sFLC), and microRNAs34. Some authors evaluated a wide 
panel of biomarkers, including cytokines and chemokines,  in HIV positive patients 
with NHL compared to HIV-positive lymphoma free control27. These studies are 
mostly retrospective and have been conducted in populations predominantly 
composed of patients who were not treated with cART prior to the diagnosis of 
AIDS-NHL35. 
 
Hodgkin lymphoma 
Hodgkin lymphoma (HL) is a B-cell derived malignancies characterized by the 
presence of malignant Hodgkin/Reed–Sternberg (HRS) cells surrounded by 
inflammatory infiltrate36. Two distinct forms of HL, known as classical Hodgkin 
lymphoma and nodular lymphocyte predominant Hodgkin lymphoma, have been 
recognized and separated on the basis of morphologic, immunophenotypic, and 
clinical differences37. In the general population, classical HL accounts for 95 % of 
cases, whereas 5 % of the patients are diagnosed with nodular lymphocyte-
predominant HL. Conversely, among PLWH the histology of HL tends to be mixed 
cellularity or lymphocyte-depleted.  
Early studies demonstrated a clear causal relationship between Epstein-Barr virus 
(EBV) infection and HIV-related HL, and is well recognized that HIV-associated HL is 
linked to EBV in 80 to 100% of cases38, while only a fraction of HL from the general 
population is EBV associated.  
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Among patients with AIDS, the onset of HL seems not be associated to the method 
of HIV acquisition (homosexual contact, intravenous drug abuse, blood transfusions, 
heterosexual contact), although the frequency perhaps is higher in people who 
abuse intravenous drugs39.  
The relation between the development of HL, immune suppression and cART is 
complex.  
Engels et al. found that Hodgkin lymphoma incidence increased substantially 
following an AIDS diagnosis, but also increased over time in association with the 
introduction of cART, confirming results from prior studies that described an 
increasing risk over time subsequent to an AIDS diagnosis, and an elevated risk 
associated with use of cART22.  
In a previous work, the same group found that as the CD4+ cells count approaches 
225-249 cells/mmc the incidence of HL increases, but as the count falls further the 
incidence declines40. These findings suggest that partial immune reconstitution with 
cART pushes the HIV infected individuals to an intermediate level of immune 
suppression that causes the highest risk of developing HL. Furthermore, it has been 
demonstrated that drops in CD4/CD8 ratio in the year prior to HL diagnosis may 
promote the onset of disease41.  
 
Kaposi’s sarcoma 
The etiologic agent of Kaposi’s sarcoma (KS) is the Human Herpesvirus-8 (HHV-8), 
also known as Kaposi’s sarcoma Herpes virus (KSHV). KSHV is mainly transmitted via 
saliva, but the routes of transmission are likely different in different populations. In 
low KSHV prevalence areas, the virus is predominantly spread among men who have 
sex with men (MSM), implicating risk factors related to sexual behavior.  
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Although KSHV transmission by blood transfusion or transplanted organs is 
documented, based on cost–benefit analyses most countries do not yet routinely 
screen blood or organ donors for KSHV infection.  
The most common cell type in nodular lesions is the spindle-shaped cells (also 
known as KS cells). The vast majority of these spindle cells express endothelial 
markers, including CD31, CD34 and Factor VIII, but also markers of lymphatic 
endothelium, such as vascular endothelial growth factor receptor 3 (VEGFR3), 
lymphatic vessel endothelial hyaluronan 1 (LYVE1), D2-40 and podoplanin42. 
Ultrastructurally, spindle cells have features of both the lymphatic and vascular 
endothelium43.  
KSHV latent transcripts, such as latency-associated nuclear antigen (LANA), viral 
cyclin, viral FLICE/caspase 8 inhibitory proteins (FLIPs) and viral-encoded microRNAs, 
drive cell proliferation and prevent apoptosis, whereas KSHV lytic proteins, such as 
viral G protein-coupled receptor, the transmembane glycoprotein K1 and virally 
encoded cytokines (viral interleukin-6 and viral chemokines) further contribute to 
the angioproliferative and inflammatory KS lesions through a mechanism called 
paracrine neoplasia44.  
However, the presence of HHV8 infection alone is not sufficient to explain the 
insorgence of KS, and a large proportion of patients infected with HHV-8 never 
develop sarcoma. The most important cofactor for the disease’s development is 
HIV-infection. The incidence of Kaposi’s sarcoma is higher among HIV-infected 
individuals with severe immune suppression, and the prevalence of KS has notably 
reduced in developed Countries since the introduction of cART45.  
Indeed, patients acquiring HHV-8 infection with pre-existing HIV infection have a 
significantly higher risk of developing KS. This suggests that an already damaged 
immune system predisposes to a higher KSHV load, with subsequent KS 
development. Antiretroviral therapy may reduce the incidence of Kaposi’s sarcoma, 
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as well that of other AIDS-related malignancies, via directly inhibiting tumor 
development and indirectly by improving the immune surveillance against tumor 
cells45. 
Moreover, chronic KSHV infection induce secretion of several pro inflammatory 
cytokines and growth factors, such as IL-6, Oncostatin M52, hepatocyte growth 
factor (also known as scatter factor)53, fibroblast growth factor 2 and vascular 
endothelial growth factor 5 (VEGF5), which in turn play a key role in driving the 
oncogenesis.  
 
HPV-related cancers 
Anal cancer, cervical cancer and oropharingeal cancers are strictly related to HPV 
infection.  
Several mechanisms may explain the high prevalence and the greater aggressiveness 
of HPV-associated diseases in HIV-positive patients. Among these, three elements 
appear to be of greater importance: direct interaction between the two viruses, 
impairment of the immune response and chromosomal instability. 
The specific cell-mediated immune response plays a fundamental role in the control 
of HPV infections in both general and in HIV-positive population.  
About 80% of sexually active individuals undergo HPV infection during life, but only 
a few develops a precancerous lesion, probably due to an effective cell-mediated 
immune response able to control and eradicate the HPV virus.46 
Similarly, it can be observed that individuals undergoing an iatrogenic 
immunosuppression secondary to organ transplantation have an increased risk of 
cervical cancer and vulvar cancer, due to the suppression of the immune response 
mandatory in this kind of patients.47 
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Little is known about this specific immune response; to date several studies have 
demonstrated a role of cytotoxic T-cells, specific for E6 and E7 HPV oncoproteins, in 
the prevention of precancerous lesions.46 
On the other hand, in general population the immune system response to HPV 
infection is weak compared to that evoked against a viral systemic infection, such as 
cytomegalovirus infection, probably due to high compartmentalization of HPV, 
which is only situated in the epithelial cells of the skin and mucous membranes48. 
Kobayashi et al. have found that in intraepithelial squamous lesions (SILs) lesions of 
HIV-positive women the concentration of immune cells (CD4 + lymphocytes, 
macrophages, neutrophils, natural killer) and the expression of interferon-gamma 
(IFN-γ) are decreased compared to the same lesions in HIV-negative 
women.48Several studies have shown a clear relationship between T-cell infiltration 
into the site of lesion and disease regression, supporting a role for adaptative T-cell 
response in lesion regression. The virus specific T-cells of the adaptative response 
consist of CD4+ and CD8+ populations. CD8+ T-cells have traditionally been thought 
to play a major role in elimination of viral infection, secreting cytokines like IFN-γ, 
interleukine-2 (IL-2) and tumor necrosis factor α (TNF-α), displaying cytolytic effects 
mediated by molecules such as granzyme and perforin, while CD4+ T-cells, which 
also secrete IFN-γ, mediate killing primarily by engagement with ligands for death 
receptors such as Fas or TRAIL, resulting in caspase-mediated apoptosis.49 
HIV infection further weakens immune response against HPV, both through 
depletion of T-cells and through down-regulation of cytokine compartment.50  
Beyond HIV-HPV co-infection, there are other factors involved in carcinogenesis: 
tobacco smoking, high parity, age at first birth, high number of sexual partners, use 
of oral contraceptives, hormone replacement therapy, dietary deficiency, history of 
sexually transmitted diseases and socioeconomic status.51 
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Hepatocellular carcinoma 
A number of disease entities have been linked to the development of hepatocellular 
carcinoma (HCC), including primary biliary cirrhosis, hemochromatosis, aflatoxin, 
and alfa1-antitrypsin deficiency. However, for the vast majority of documented HCC, 
the primary pathogenetic role is played by Hepatitis C virus (HCV), Hepatitis B virus 
(HBV) and cirrhosis. Cirrhosis underlies HCC in more than 80% of the cases, and the 
predominant cause of cirrhosis are HCV and HBV, with a minority of cases sustained 
by alcohol abuse52.  
HIV, HCV and HBV share common transmission patterns, which explains the 
frequent co-infection with HIV and one or both hepatotropic virus. Moreover, HIV 
infection can alterate the natural history of HCV and HBV infection, and co-infected 
patients show a more rapid progression of viral hepatitis to liver inflammation and 
cirrhosis53, even with HIV replication under full control by cART.54 
Even though HIV itself is not a direct causative agent of HCC, it can fasten the time 
of progression to fibrosis and cirrhosis through complex mechanisms involving 
immune suppression and chronic immune activation. 
The role of immune status, including CD4+ cells count at the time of cancer 
diagnosis and nadir CD4+ count,  has been studied although not fully clarified.  
In the Swiss Cohort55, the risk of HCC was associated with low CD4+ cell count in the 
year preceding cancer diagnosis. Conversely, a recent study demonstrated that  
although cumulative HIV-related immune suppression (nadir CD4+ count, percent of 
time with undetectable HIV viral load) were not associated with HCC, immune 
suppression at the time of HCV diagnosis, as measured by CD4+ cell count, was 
associated with the risk of cancer.56  
It is likely that, beyond CD4+ cell count, the persistent perturbation of the immune 
response and the cytokines network play a major role in the pathogenesis of HCC.  
CD4+ cells depletion may  promote hepatic fibrosis through the decreased secretion 
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of the anti-fibrotic T-helper (Th) 1 cytokine gamma-interferon (IFN-γ). On the other 
hand, the increased Th2 response is associated with secretion of Th2 cytokines with 
a recognized pro-fibrotic role (IL-4, IL-5, IL-10, and IL-13)57.  
 A study conducted on 52 HBV mono-infected and 54 HIV/HBV co-infected patients 
demonstrated higher levels of pro-inflammatory markers in co-infected patients, 
such as Interleukine-6 (IL-6) and soluble CD14 (sCD14), suggesting an enhanced pro-
inflammatory response in this group.58 Further, microbial translocation consequent 
to CD4+ depletion in the gastrointestinal tract has been linked to liver fibrosis in 
HIV/HCV co-infection, trough the subsequent chronic inflammation and immune 
activation59 60.  
Finally, former or active use of drugs and alcohol abuse have to be considered as 
potential factors involved in the process of liver disease progression, as a large 
proportion of HIV/HCV positive patients are active/ex intravenous drug users (IDUs) 
and heavy alcohol consumers61 62. Of note, beyond heroine, other substances such 
as cannabis, cocaine and amphetamine may potentially cause liver damage and 
worsening of fibrosis54 63 64.  
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Co-infection with oncogenic virus occurs as a key pathogenic factor in AIDS-defining 
malignancies (ADMs) (namely, Non-Hodgkin lymphoma (NHL), Kaposi sarcoma (KS), 
anal and cervical cancer) and in some non-AIDS defining malignancies (NADMs) (anal 
cancer, haepatocellular carcinoma (HCC) and Hodgkin lymphoma (HL).  
Beside co-infection with oncogenic virus, the pathogenic pathways underlying the 
development of infection-related and non infection-related cancer in people living 
with HIV (PLWH) are sustained by a  complex network of interactions between 
various components of the immune system, with cytokines and other pro-
inflammatory agents mediating those interactions. However, these mechanisms 
have not been fully characterized.  
CD4+/CD8+ ratio is correlated with markers of immune activation and immune-
senescence, such as lower levels of peripheral naïve T-cells and increased proportion 
of terminally-differentiated T-lymphocytes. The normalization of CD4+/CD8+ ratio 
above 1 is slow even during suppressive combination antiretroviral therapy (cART), 
mainly due to the persistent expansion of the CD8 T-cells compartment65, and 
reflect persistent immune activation in PLWH66. A recent study conducted in the 
Swiss cohort demonstrated that the risk to develop Hodgkin lymphoma, a non-AIDS-
related but Epstein-Barr virus (EBV)-triggered cancer, was higher in patients with 
very low CD4+/CD8+ ratio (<0.25). On the other hand, the expression of the immune 
activation marker CD38 on CD8T-lymphocytes has been linked with HIV infection 
progression and immune senescence, even in the contest of suppressive cART. It’s 
role in cancer pathogenesis in PLWH has been poorly studied. 
Moreover, In the context of HIV-associated lymphoma, there is considerable interest 
in the role of natural killer (NK, CD56+) cells, as they may contribute to the host 
response to anticancer therapy32.   
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Finally, we focused on the demographic and immunological factors that promote 
HPV persistence and carcinogenesis in HIV positive patients, as anal and cervical 
cancers are highly prevalent amongst PLWH.  
In this context, the aims of this study were:  
- to assess the association of peripheral immune activation markers 
(CD8+CD38+ T-lymphocytes) and CD4/CD8 ratio with the onset of infection-
related and non-infection related cancers in a cohort of HIV-positive patients, 
and possible association of these markers with overall survival. 
- To evaluate the natural killer (NK) cells population in a cohort of HIV positive 
patients with diagnosis of lymphoma and possible association with the overall 
survival.  
- To evaluate possible factors associated with Human Papilloma virus (HPV) 
infection at anal and cervical site and with the presence of precancerous 
lesions (squamous intraepithelial lesions-SILs) in a cohort of HIV-positive 
patients with focus on gender differences, and possible factors linked with the 
capability to clear HPV infection, thus influencing the progression of  SILs 
towards cancer. 
 
 
We thus performed the following studies:  
- Association of T-cells activation markers and CD4/CD8 ratio with virus related 
and non-virus related cancers in HIV-positive patients. 
- Natural Killer cell populations in HIV associated lymphoma. 
- Sex-based differences in factors associated with HPV infection and 
intraepithelial lesions in a cohort of HIV-positive patients. 
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Materials and methods 
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For the following studies:  
- Association of T-cells activation markers and CD4/CD8 ratio with virus related 
and non-virus related cancers in HIV-positive patients; 
- Sex-based differences in factors associated with HPV infection and 
intraepithelial lesions in a cohort of HIV-positive patients; 
we enrolled antiretroviral-naive and cART-treated HIV-infected patients in active 
follow up at the SPID (San Paolo Infectious Disease) Cohort. The SPID cohort was set 
up in 2006 and includes all HIV positive patients who are attending the outpatients 
service of Infectious Diseases’ Clinic at San Paolo Hospital, Milan, Italy. To date, 1127 
patients are included, 1069 with active follow up, with a median age of 45 years; 
795 (74%) are males and 1008 (94%) are on cART. 
According to the study they were enrolled in, consecutively visited HIV-positive 
female and male patients signed an informed consent for anal/genital cancer 
screening from October 2002 to February 2016. Inclusion criteria were: to be HIV 
positive, older than 18 years, without history of HPV vaccine, asymptomatic for 
genital distress or discharge. Exclusion criteria were: refusal to sign the informed 
consent. Both therapy-naive patients and subjects receiving cART were included.  
 
Lymphocyte subsets were evaluated by flow cytometric analysis, using 50 μl 
ethylenediaminetetraacetic acid (EDTA) peripheral blood incubated for 30 min at 
4°C with fluorochrome-labeled monoclonal antibodies (mAbs) (CD4+, CD8+, CD38+, 
CD8+/CD38+). After incubation, erythrocyte lysis and fixation of marked cells were 
performed using the Immuno-Prep EPICS kit and Q-prep Work Station (Coulter 
Electronics, Hialeah, FL, USA). The CD4+/CD8+ ratio was calculated as a ratio of the 
absolute CD4+ and CD8+ cell counts. 
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For the study:  
- Natural Killer cell populations in HIV associated lymphoma  
we enrolled HIV-positive patients of the National Centre for HIV malignancies, 
Chelsea and Westminster Hospital, London (UK). At the Centre, the routine data on 
all individuals who attend are prospectively collected, including 615 HIV seropositive 
patients diagnosed with lymphoma between 1988 and 2017. Data on patient 
characteristics, prognostic factors, treatment and outcomes were extracted from 
the database. 
For the immune subset analysis, total lymphocyte and subset analysis was 
performed using whole blood stained with murine antihuman monoclonal 
antibodies to CD4 (T helper cells), CD8 (a cytotoxic T-cell marker), CD19 (B cells), and 
CD16/56 (natural killer cells) (TetraOne; Beckman Coulter, High Wycombe, United 
Kingdom) and were evaluated on an Epics XL-MCL (Beckman Coulter) 
multiparametric 4-color flow cytometer.  
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Association of T-cells activation markers and CD4/CD8 ratio with 
virus-related and non virus-related cancers in a cohort of HIV 
positive patients.  
 
 
Introduction 
Co-infection with oncogenic virus occurs as a key pathogenic factor in AIDS-defining 
malignancies (ADMs), namely Non-Hodgkin lymphoma (NHL), Kaposi sarcoma (KS) 
and cervical cancer, and in some non AIDS-defining malignancies (NADMs), such as 
anal cancer, haepatocellular carcinoma (HCC) and Hodgkin lymphoma (HL). 
However, beside co-infection with oncogenic virus, the pathogenic pathways 
underlying the development of infection-related and non infection-related cancer in 
people living with HIV (PLWH) are sustained by a  complex network of interactions 
between various components of the immune system, with cytokines and other pro-
inflammatory agents mediating  those interactions, which have been only partially 
characterized. 
Thus, beyond immune suppression as measured by CD4+ cells count, the 
identification of markers of perturbation of the immune-subsets and of chronic 
inflammation has been advocated to predict the risk of cancer in PLWH. 
CD4+/CD8+ ratio is correlated with markers of immune activation and immune-
senescence, such as lower levels of peripheral naïve T-cells and increased proportion 
of terminally-differentiated T-lymphocytes. The normalization of CD4+/CD8+ ratio 
above 1 is slow even during suppressive combination antiretroviral therapy (cART), 
mainly due to the persistent expansion of the CD8 T-cells compartment65, and 
reflect persistent immune activation in PLWH66.  
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Failure in reaching a normal CD4/CD8 ratio has been associated with the risk of non-
AIDS defining events globally, and especially with the risk of non-AIDS defining 
cancers in PLWH66. On the other hand, the expression of the immune activation 
marker CD38 on CD8T-lymphocytes has been linked with HIV infection progression 
and immune senescence, even in the contest of suppressive cART, and contributes 
to the pathogenesis of both AIDS and non-AIDS associated diseases67.  
Thus, we aimed to assess the association of CD4+/CD8+ ratio and CD8+CD38+ with 
the onset of virus related and non virus-related cancers in a cohort of HIV-positive 
patients, and the possible influence of these markers on mortality in our cohort.  
 
 
 
Patients and methods 
Study design and study population 
The SPID (San Paolo Hospital Infectious Disease) cohort was set up in 2006 and 
includes all HIV positive patients who are attending the outpatients service of 
Infectious Diseases’ Clinic at San Paolo Hospital, Milan, Italy. To date, 1127 patients 
are included, 1069 with active follow up, with a median age of 45 years; 795 (74%) 
are males and 1008 (94%) are on cART. 
We included in the present study all the consecutively visited HIV-positive patients 
who received a diagnosis of infection-related and non-infection related cancers from 
January 2000 to August 2018. Both therapy-naive patients and subjects receiving 
cART at the time of cancer diagnosis were included.  
Prospectively collected clinico-pathologic and treatment data on all individuals 
included where analyzed.   
Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma (HL), Kaposi’s sarcoma (KS), 
HPV-related cancers (cervical cancer, anal cancer, laryngeal cancer), hepatocellular 
carcinoma (HCC) were classified as infection-related cancers. Lung cancer, breast 
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cancer, prostate cancer, colorectal cancer, thyroid cancers were classified as non 
infection-related cancers.  
 
T- lymphocyte subsets 
Lymphocyte subsets were evaluated by flow cytometric analysis, using 50 μl 
ethylenediaminetetraacetic acid (EDTA) peripheral blood incubated for 30 min at 
4°C with fluorochrome-labeled monoclonal antibodies (mAbs) (CD4+, CD8+, CD38+, 
CD8+/CD38+). After incubation, erythrocyte lysis and fixation of marked cells were 
performed using the Immuno-Prep EPICS kit and Q-prep Work Station (Coulter 
Electronics, Hialeah, FL, USA). The CD4+/CD8+ ratio was calculated as a ratio of the 
absolute CD4+ and CD8+ cell counts. 
 
Statistical analysis:  
Data were presented as absolute numbers, percentages and median, interquartile 
range (IQR) for categorical and quantitative variables, respectively. Comparisons 
between patients with virus-related cancer versus non virus-related cancer were 
assessed by Chi-square test for nominal variables and non parametric Mann-
Whitney test for continuous variables. The same analysis were conducted to explore 
factors associated with virus-related and non virus-related cancers in the group of 
patients on cART at the time of cancer diagnosis. 
The time interval from cancer diagnosis until death, study censoring or loss to 
follow-up was used to calculate overall survival. Survival curves were plotted 
according to the method of Kaplan and Meier68. The log rank method was used to 
test for the significance of differences in survival distributions.  
Analyses were conducted using SPSS (SPSS, version 21.0). 
 
Results: 
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140 patients had a cancer diagnosis between 1/01/2000 and 27/06/2018, 115 (82%) 
virus related and 25 (18%) non virus-related. 114/140 ( 81%) patients were males 
and the median age of the entire study population at the time of cancer diagnosis 
was 47 years (IQR: 39-52). 37/140 patients (26%) had a diagnosis of AIDS-related 
disease preceding or concomitant to the diagnosis of cancer and 77/140 (55%) were 
on cART at the time of cancer diagnosis.  
The clinico-pathological characteristics of study population by virus-related and non 
virus related cancers are shown in table 1.  
Patients with virus-related cancers were younger compared with patients with non 
virus-related cancers (44 yrs, 36-51 vs. 56 yrs 48-61 p<0.001), more frequently males 
(99/115, 86% vs. 15/25, 60% p=0.002) and MSMs (62/115, 53% vs. 7/25, 28% 
p=0.003).  Moreover, virus-related cancer patients were more recently diagnosed 
with HIV infection compared to non virus-related cancers patients (median, IQR: 48 
months, 0.25-158 vs. 144 months, 26-239 p=0.04) and less frequently on cART at the 
time of cancer diagnosis (57 pts, 51% on cART vs. 20 pts, 80% on cART p=0.007).  
Accordingly, CD4+ cells count (median, IQR: 219 cells/mmc, 112-481 vs. 400 
cells/mmc, 305-563 p=0.004) was lower in patients with virus related-cancer. 
The CD4+/CD8+ ratio was <1 in both the groups of patients, with significantly lower 
values in the group of virus-related cancer compared to non virus-related cancer 
(median, IQR: 0.33 0.14-0.60 vs. 0.54, 0.34-0.73 p= 0.01).  
Nadir CD4+ (p=0.97) and CD8+CD38+ as cells count (p=0.99) and percentage 
(p=0.08)  were comparable in the two groups of patients .  
Given the higher percentage of patients on antiretrovirals among individuals with 
virus-related cancer, we conducted the same comparisons in the group of patients 
on cART (77/140, 55%) at the time of cancer diagnosis (Table 2).  
Patients on cART with infection related and non infection-related cancer were 
comparable for length of HIV infection (median, IQR: 138 months, 29-229 vs.  163 
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months, 51-256 respectively, p=0.38), percentage of patients on virological 
suppression (33 pts, 58%  vs. 15 pts, 75% respectively, p=0.203), nadir CD4+ 
(median, IQR: 118 cells/mmc, 49-225 vs. 128 cells/mmc, 84-209 p=0.93) and 
prevalence of previous or concomitant AIDS disease (18/57 patients, 31% vs.7/20 
35% p=0,51). However, patients with virus-related cancer had been exposed to cART 
for a shorter length of time at the time of cancer diagnosis (median, IQR: 59 months, 
19-186) compared to patients with non virus-cancer (median, IQR: 180 months, 81-
239, p=0.01).   
Lower CD4+cell count (median, IQR: 280 cells/mmc, 152-556 vs. 414 cells/mmc, 305-
608 p=0.025) and younger age (median, IQR: 48 yrs, 40-52 vs. 57 yrs, 51-65 p<0.001) 
were associated with virus-related cancer; nevertheless, among cART treated 
patients, the CD4+/CD8+ ratio was <1 in both groups without differences between 
infection-related and non infection-related cancer (median, IQR: 0.47, 0.25-0.71 in 
virus-related cancer vs. 0.59, 0.38-0.83 in non infection-related cancer, p=0.21)  .  
 
Survival data 
96/140 patients were treated with curative intent with systemic chemotherapy 
and/or surgery according to cancer type. 38/140 patients were treated with cART 
alone as they had a diagnosis of T0 stage KS. 6/140 patients received best 
supportive care.  
39/140 (28%) patients died during follow up, 28/39 (72%)  with virus related cancer 
and 13/39 (33%)  with non virus related cancer. 
For 23/39 patients the cause of death was progressive disease, 3 patients died for 
intercurrent AIDS-defining disease (namely, neurotoxoplasmosis, micobacteriosis 
and IRIS KS), 3 patients for chemoteherapy related-cause. 10 patients died for 
unrelated causes in remission.  
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After a median follow up of 177 months (95% CI: 147-207), the 5 yrs probability of 
death for the whole population was 28% (95% CI: 19-35%).  
When we compared the Kaplan-Meier survival curves of patients with infection and 
non infection-related cancer, we found that the 5 yrs probability of death was 22% 
(95% CI: 13-29) for infection-related cancers vs. 56% (95% CI: 34-78) for non-
infection related cancer (log rank p=0.004).  
The influence of low CD4+/CD8+ ratio (CD4+/CD8+ <4) and CD8+CD38+ percentage 
on mortality was evaluated using a Cox proportional hazards model. Neither 
CD4+/CD8+<4 (p=0.75) nor CD8+/CD38+ percentage (p=0.79) were prognostic 
variables for overall survival.  
 
 
 
Discussion 
 
Among PLWH, different type of malignancies with and without a known viral-trigger 
display different strength of association  with immune suppression as measured by 
CD4+, and the risk excess for cancer observed in PLWH persist after cART 
introduction, which is now anticipated to restore the CD4+ cell count. Moreover, 
among non-AIDS related malignancies, a number of cancer types do have a 
recognized viral-triggered origin, and could present in the contest of more 
dysfunctional immune subset compared to non-virus related cancer.  
In this study we aimed to assess the association of CD4+/CD8+ ratio and 
CD8+CD38+, both markers of immune deregulation, with the onset of virus related 
and non virus-related cancers.  
We found that patients with a cancer with known viral-origin were younger and less 
frequently on antiretrovirals at the time of cancer diagnosis compared with patients 
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with non-infection related cancer. Accordingly, they showed deeper levels of 
immune suppression as measured by CD4+ cell count. This may be mostly ascribable 
to the inclusion into viral-related cancers of KS and NHL, which are strongly related 
to advanced immune suppression; on the other hand, other virus-related cancer, 
namely HL and HCC, clearly have a weaker relationship with immune suppression69. 
Due to the low number of cases, we were not able to explore the effect of CD4+ T- 
cell count on specific types of cancers. 
Peripheral levels of CD8+CD38+ were comparable in the two groups, with no 
difference between virus and non-virus related cancer. This is surprising, because 
higher levels of CD8+CD38+ are observed in the contest of several acute and chronic 
infections70,  and tend to decline when viral replication is suppressed. It could be 
hypothesized that  the high burden of antigenic stimulation in infection-related 
cancer during HIV infection can lead to CD8 T-lymphocyte cell dysfunction or 
exhaustion, as has been demonstrated in the contest of primary HIV-infection.71 
In both the groups, the CD4+/CD8+ ratio was below 1 at the time of cancer 
diagnosis, but the median CD4+/CD8+ ratio was significantly lower in virus-related 
cancer compared to non virus-related cancer. However, when we analyzed patients 
on cART at the time of cancer diagnosis, the ratio was <1 for both virus-related and 
non virus-related cancer without  significant differences between the two groups. In 
our cohort, patients with virus-related cancer had been on antiretrovirals for a 
significantly shorter time compared to non virus-related cancer. These data support 
the hypothesis that cART, even though for short time of exposure, can partially 
revert, though not completely restore, the CD4+/CD8+ ratio, even in the contest of 
infection-related malignancies.    
 
Our finding that malignancies with a known viral origin had a lower 5 yrs risk of 
death compared to non-infection-relate cancer may be attributable to the presence, 
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among the former group, of KS and cervical cancer, which are burdened by low 
mortality; alternatively, the higher 5-yrs probability of death among non virus-
related cancer may be linked to older age, and further stratified analysis are 
necessary to clarify this difference.   
Immune-activation has been widely studied as a risk factor for several non-
communicable disease in PLWH, including cancer72, and has been indicated as a 
predictor of mortality in HIV-positive patients with history of AIDS. However, in this 
study, we did not find an association between immune-activation or CD4+/CD8+ 
ratio and mortality. It is possible that levels of immune activation in our cohort 
reflect the presence of persistent inflammatory stimuli, that drive mortality through 
parallel pathways.  
Indeed, the role of CD4+/CD8+ ratio in predicting AIDS and non-AIDS related 
morbidity and mortality has not been fully clarified.  
A large study involving Infectious Disease centers in Europe and North America 
failed to demonstrate an association between CD4+/CD8+ and  all-cause mortality in 
a HIV population with high CD4+ counts and suppressed viral load73. Both low 
CD4+/CD8+ ratio and high CD8+ count were associated with AIDS mortality in this 
population, suggesting that both CD4+/CD8+ ratio and CD8 count could account for 
some excess AIDS mortality in a HIV population that was otherwise healthy. A recent 
study showed that  the CD4+/CD8+ ratio did not add predictive information on 
morbidity to the CD4+ cells count, except for non-AIDS cancers74.  It is likely that 
associations may only be with specific causes of death, that we were unable to look 
at in this study. Indeed, a major limitation of this study is small sample size, and 
larger cohort analysis would allow to better interpret survival data.  
 
In conclusion, we found that immune-activation at the onset of cancer was similar in 
patients with infection and non infection-related malignancies.  
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Patients with infection-related cancer had lower CD4+/CD8+ ratio, but this 
difference was no longer significant among patients on cART, supporting the 
importance of a prompt initiation of cART in contrasting the immune-deregulation in 
both virus and non-virus related malignancies.  
In this study,  CD8+CD38+ and CD4+/CD8+ ratio were not predictive of outcome in 
HIV-positive patients with cancer.  
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Natural Killer cell populations in HIV associated lymphoma 
 
Introduction 
 
Cancer is a leading cause of morbidity and mortality in people living with HIV 
(PLWH),particularly since the advent of combination antiretroviral therapy (cART). 
After Kaposi sarcoma, non-Hodgkin lymphoma (NHL) is the most common 
malignancy in PLWH75. The pathogenic pathways underlying the development of 
lymphoma in PLWH suggest a complex network of interactions between 
components of the immune system, with cytokines and other pro-inflammatory 
agents mediating many of these interactions. In this context there is considerable 
interest in the role of natural killer (NK) cells as they may contribute to the host 
response to anticancer therapy32. 
NK cells are characterized by a CD3-/CD56+ phenotype and include two 
subpopulation defined on the basis of CD56 and CD16 expression. The majority of 
circulating NK cells (>90%) are CD56dim, express CD16, and exert cytotoxic activity 
against tumor cells. The minority are CD56bright NK cells with low or absent CD16 
expression and are generally confined to lymph nodes.CD56bright NK cells have 
limited cytotoxic activity and predominantly exhibit immune-regulatory functions 
through cytokines production upon stimulation76 77 . 
In HIV-negative patients, NK cells constitute a higher percentage of circulating 
lymphocytes and are associated with a better outcome in both Hodgkin lymphoma 
and diffuse large B-cell lymphoma (DLBCL)78. On the other hand, NK cell number and 
function are impaired during chronic HIV infection79. Furthermore, low CD4+ T-cells 
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count has been linked with depletion of the NK cells compartment in patients with 
AIDS-related lymphoma, suggesting a poor prognosis80 
In this study we aim to evaluate the NK cell compartment in a large cohort of PLWH 
with NHL, and its possible association with the outcome of anticancer treatment in 
DLCBCL.  
 
Methods 
Patient selection and data collection 
At the National Centre for HIV malignancies at the Chelsea and Westminster 
Hospital we prospectively collect routine data on all individuals who attend, 
including 615 HIV seropositive patients diagnosed with lymphoma between 1988 
and 2017. Data on patient characteristics, prognostic factors, treatment and 
outcomes were extracted from the database. 
 
Immune subsets 
Total lymphocyte and subset analysis was performed using whole blood stained with 
murine antihuman monoclonal antibodies to CD4 (T helper cells), CD8 (a cytotoxic T-
cell marker), CD19 (B cells), and CD16/56 (natural killer cells) (TetraOne; Beckman 
Coulter, High Wycombe, United Kingdom) and were evaluated on an Epics XL-MCL 
(Beckman Coulter) multiparametric 4-color flow cytometer.  
 
Statistical analysis 
Comparison of variables between the groups was by Chi-squared test for categorical 
data and Kruskal-Wallis test for non-parametric continuous variables; all p values 
are two-sided. The association between CD4+T-cells count and NK cells count was 
assessed by bivariate analysis. The time interval from lymphoma diagnosis until 
death, study censoring or loss to follow-up was used to calculate overall survival. 
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Survival curves were plotted according to the method of Kaplan and Meier68. The log 
rank method was used to test for the significance of differences in survival 
distributions81.  
The study complied with local regulations and was approved by the institutional 
review boards of Chelsea and Westminster Hospital. Patient details were 
anonymized and therefore patient consent was not required.  
Results 
Full lymphocyte subset analysis at lymphoma diagnosis was available for 361 
patients (271 high grade B-cell NHL and 90 HL). Among the 271 patients with NHL, 
157 (58%) had DLBCL, 62 (23%) Burkitt lymphoma, 18 (6%) primary effusion 
lymphoma, 17 (6%) plasmablastic lymphoma and 17 (6%) primary cerebral 
lymphoma (PCL). For these 271 patients (229 (84%) were male and the mean age at 
NHL diagnosis was 43 years (range 19-75). The median duration of HIV infection at 
NHL diagnosis was 31 months (range 1-295), 57 (21%) had a prior AIDS diagnosis and 
153 (56%) were established on cART, of whom 60% had an undetectable plasma HIV 
viral load. The clinicopathological features and International Prognostic Index (IPI) 
scores for the 157 patients with DLBCL are shown in table 3. 
 
 
Lymphocyte subsets at baseline 
The median CD56+ cells count was below the reference threshold (normal range: 
90-600 cells/mm3) irrespective of histology, without significant differences between 
the histological groups; however, the NK cells as a percentage of total lymphocyte 
counts was significantly higher in patients with HL (median 9%) than in DLBCL 
(median 6%) and other NHL subtypes (p=0.009).  
As expected, CD4+ T-cells count and percentage were low in all histology groups, 
with the lowest valuesin patients with PCL (median79 cells /mm3) compared to 
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other groups (p=0.01). Similarly, CD19 B-cell counts and percentages were lower in 
HL (median 58 cells/mm3) than in NHL histological groups. See Table 4. 
 
For the whole group of 361 patients, CD56+ cell count was positively associated with 
CD4+ T-cell count although thecorrelation coefficient between the variables was 
very weak (R2=0.11, Figure 2A). On the other hand, plasma HIV viral suppression 
(recorded as below the level of detection in assay used at the time of analysis) was 
strongly associated with higher CD56+ cell count and percentage at the time of 
lymphoma diagnosis (p<0.0001) (Figure 2B).  
 
 
Survival data and prognostic factors analysis 
Of the 157 patients with DLBCL, 149 were treated with curative intent with 
combination chemotherapy; 83 R-CHOP (rituximb, cyclophosphamide, doxorubicin, 
vincristine and prednisolone), 63 CDE (cyclophosphamide, doxorubicin and 
etoposide), 2 R-CODOX-M/IVAC (rituximab, cyclophosphamide, doxorubicin, 
vincristine, methotrexate / ifosfamide, etoposide, cytarabine). The median follow-up 
for these 149 patients is 8.5 years (maximum 18.5) and the 5 year overall survival is 
66% (95%CI: 58-74%)(See Figure 2). See table 3 for clinicopathological details of 
these 149 patients. Thirty-one patients have died of NHL (15 refractory and 16 
relapsed lymphoma), 10 died of chemotherapy related causes and 9 died in 
remission. 
The IPI group score was strongly associated with overall survival for 149 patients 
with DLBCL who were treated with curative intent (Log rank proportional hazards 
p<0.0001). The influence of NK cell population on overall survival was evaluated 
using a Cox proportional hazards model stratified for IPI. Neither total NK cell 
population (p=0.62) nor NK cells as a percentage of lymphocytes (p=0.76) were 
prognostic variables for overall survival. Similarly, CD4 (p=0.73), CD4% (p=0.37), CD8 
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(p=0.86), CD19 (p=0.99) and CD19% (p=0.10) did not influence overall survival. 
However, CD8% was significantly associated with overall survival(p=0.034) in the 
stratified model although without stratification for IPI, CD8% did not predict survival 
(p=0.17).  
 
Discussion:  
NK cells are large granular lymphocytes that express neither surface 
immunoglobulins nor T-cell receptors. They are an important mediator of innate 
immune responses recognizing and destroying “stressed” cells including viral 
infected cells and tumour cells. These cells are recognized by NK cells because they 
lack self-molecules including MHC class I. Following NK cell activation by this 
recognition, perforin and granzymes are released resulting in the death of target 
cells by apoptosis. Thus NK cells have an important role in the innate defense 
against virus infected cells and cancer cells. Previous studies have demonstrated 
reduced numbers of NK cells in PLWH79 and this could contribute to the survival of 
virus infected cells including Herpesvirus infected lymphoid cells that are the origin 
of most HIV associated NHL.  
In this cohort study we found that the median NK cell count at lymphoma diagnosis 
was below the reference threshold and that the NK cell count expressed as a cells as 
a percentage of total lymphocyte counts was significantly lower in patients with 
AIDS defining lymphomas than in HL (p=0.009). As expected, CD4+ T-cells count and 
percentage were low in all histology groups, with the lowest values in patients with 
PCL (median 79 cells /mm3) but highest in HL (median 271 cells/mm3). Whilst overall 
CD56+ cell counts were positively associated with CD4+ T-cell counts, the correlation 
coefficient between the variables was very weak (R2=0.11). These findings support 
the hypothesis that loss of CD56+ cells could contribute to lymphoma development 
in PLWH, especially the AIDS defining non-Hodgkin lymphomas. Of course this 
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analysis does not include a control group of PLWH who do not have lymphomas and 
it is not possible to correct for other confounding variables.  
 
A low NK cell count at diagnosis has been shown to be associated with adverse 
outcome in a trail that enrolled 140 HIV negative patients with poor risk DLBCL who 
were treated with induction anthracycline based chemotherapy followed by 
autologous stem cell transplantation. Indeed circulating NK cell count was inversely 
associated with response rate and event-free survival in multivariate analysis 
independent of IPI78. In contrast, in this study, we found no correlation between 
total NK cell count (or NK cells as a percentage of lymphocytes) and overall survival 
in 149 patient with HIV associated DLBCL. There are several possible explanations 
for the different findings in PLWH. Firstly, the median NK cell count at lymphoma 
diagnosis was 104 cells/mm3 in the HIV negative cohort but only 63 in our patients. 
Secondly, only 37 (26%) HIV negative patients received rituximab as part of their 
treatment whilst in our cohort 86 (58%) received rituximab. This is important 
because antibody-dependent cellular cytotoxicity is largely mediated by NK cells 
because cells oposonised with antibodies can be recognised by FcϒRIII (CD16) 
receptors expressed on NK cells, leading to NK cell activation and target cell 
apoptosis(10). A further limitation, in both studies, is lack of functional assessment 
of NK cell activity, specifically the expression of activating and inhibitory receptors 
whose balance determines the anticancer activity of NK cells82.  
 
Indeed the precise role of NK cells in contributing to the efficacy of therapeutic 
antibodies has not been fully clarified. However, strategies that enhances the ADCC 
of NK cells and the capability of monoclonal antibody to boost NK-related citoxicity 
have been explored in HIV-negative patients83 84 85. Specifically, the use of 
immunemodulatory antibodies has shown to be promising86 87 . 
49 
 
A recent study85 compared UL16-binding protein (ULBP) 2 and B7 homolog 6 (B7-
H6), two ligands of the NK activating receptors NK2GD (natural killer group 2 
member D) and NKp30, in terms of capability to boost the NK ADCC. ULBP2 and 
B7H6 were fused with a single chain fragment variable of the CD20 antibody 7D8 
and both the immune ligands (ULBP2:7D8 and B7H6:7D8) promoted in vitro the 
ADCC induced by the monoclonal antibodies rituximab and daratumumab 
synergistically; this indicates that the co-engagement of FcϒRIII and either NK2GD 
and NKp30 enhances NK citotoxity, and could promote the efficacy of therapeutic 
antibodies.   
A further approach is to quantitatively increase the effector cells involved in ADCC. 
This has been obtained by stimulating human peripheral mononuclear cells with 
interleukin 2 (IL-2) to generate lymphokine-activated killer (LAK) cells, that contain 
NK cells88 89 90. Recently,  in a clinical trial including 12 patients with follicular 
lymphoma51, the increased expansion of NK cells within the LAK pool has been 
shown to correlate with cytotoxicity against CD20-positive tumor cells and with 
rituximab-related ADCC in vivo. LAKs were administered in those patients together 
with rituximab as a maintenance therapy after 6 cycle of R-CHOP, and this is 
important with a view to attempt to eradicate CD20-positive cells and to prevent 
tumor relapse.    
 
Our study indicates that NK cells deficiency is a key point in the development of non-
Hodgkin lymphoma in PLWH and could explain, at least in part, the higher risk for 
malignancies that persists in the cART era.  
However, a lower NK cells count was not associated with a worse overall survival of 
our  patients with DLBCL, possibly because of a functional impairment beyond their 
quantitative depletion.  
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The function of NK cells in the setting of HIV-associated lymphoma may indeed have 
different features from those observed in the HIV-negative population. Since in HIV-
negative patients immunotherapy targeting NK cells is promising, further studies in 
PLWH may allow comprehending whether NK-cells antitumor function could be 
restored in these patients, and consequently exert their potential to boost the 
response to chemotherapy.  
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Sex-based differences in factors associated with HPV infection 
and intraepithelial lesions in a cohort of HIV-positive patients 
 
 
Introduction 
 
Human Papilloma Virus (HPV) infection is the most common sexually transmitted 
disease worldwide and its persistence is associated with several types of cancers91 92. 
Despite the advent of combination antiretroviral therapy (cART), HIV-positive 
patients present a several fold greater incidence of cervical cancer93 and  30 to 100-
fold higher incidence rate of anal cancer compared to the HIV-negative population16 
94 95. To date, three vaccines (bivalent, quadrivalent and nonavalent) have been 
licensed for the prevention of infection by the most diffused high-risk (HR) and low-
risk (LR) HPV genotypes and showed also high efficacy in preventing cervical and 
anal intraepithelial lesions 96 5. 
The effect of HIV on the natural history of HPV infection is still a matter of debate, 
since 
many elements affect a full characterization of  the factors that promote HPV 
persistence and carcinogenesis in HIV positive patients: the host and virus-related 
variations in the immune capability to clear the infection, the different 
susceptibilities to infection by anatomic site, the influence of risky behaviors97 98. 
Further, the role of cART on HPV infection and on intraepithelial lesions is still 
unclear. Some studies demonstrated an increased incidence in anal cancer and no 
significant change in the overall incidence of cervical cancer among HIV-positive 
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individuals between 1992 and 2003, while others reported that cART significantly 
decreased the risk of cervical cancer but not anal cancer.99 100 101Indeed, few studies 
assessing the natural history of HPV infection include men and women from the 
same cohort or setting, since the vast majority of reports derives from cohorts 
composed by HIV positive men who have sex with men (MSM) or women only, or 
assessed the natural history of HPV among heterosexual couples100 102.  
It has been hypothesized that HPV infection could persist independently from CD4+ 
T-cells count in female population; thus, HPV natural history might be mostly linked 
to behavioral factors and traditional risk factors, such as infection with high risk HPV 
genotype (HR-HPV genotype) or co-infection with multiple HPV genotypes.  
Palefsky et al. demonstrated that higher CD4+ T-cells count in men who have sex 
with men does not necessary protect against intraepithelial anal lesion 
development103 17, while other authors found a protective effect of prolonged cART 
(same regimen received for 4 years or more) against grade 2 and 3 anal 
intraepithelial neoplasia (AIN 2-3), after adjusting for nadir CD4+ T-cells count104.   
The aim of our study was to assess the prevalence and the factors associated with 
HPV infection and with intraepithelial lesions at anal and cervical site in a cohort of 
HIV-positive men and women asymptomatic for HPV cared at the same clinical 
center. We further investigated possible factors linked with the capability to clear 
HPV infection, thus influencing the progression of intraepithelial lesions towards 
cancer.  
 
Patients and methods 
Study design and study population 
The SPID (San Paolo Hospital Infectious Disease) cohort was set up in 2006 and 
includes all HIV positive patients who are attending the outpatients service of 
Infectious Diseases’ Clinic at San Paolo Hospital, Milan, Italy. To date, 1127 patients 
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are included, 1069 with active follow up, with a median age of 45 years; 795 (74%) 
are males and 1008 (94%) are on cART. 
We included in the present study all the consecutively visited HIV-positive female 
and male patients who signed an informed consent for anal/genital cancer screening 
from October 2002 to February 2016. Patients were diagnosed and treated 
according to national guidelines and agreements. All data analysed were collected 
as part of routine diagnosis and treatment. Further, every patient signs a consent 
form for collection of body samples (blood, biopsies) and clinical data at the first 
clinical visit at our centre. The form has been approved by the ethics committee of 
our centre.  
Inclusion criteria were: to be HIV positive, older than 18 years, without history of 
HPV vaccine, asymptomatic for genital distress or discharge. Exclusion criteria were: 
refusal to sign the informed consent. Both therapy-naive patients and subjects 
receiving cART were included.  
Each patient underwent blood exams at baseline. At the same time point (time of 
first visit), women underwent a gynaecological evaluation with colposcopy and 
cervical swab. Men underwent a surgical visit with anoscopy and anal swab. A 
longitudinal study was performed on an unselected subgroup of patients who 
repeated the same evaluation after 12-24 months. 
Blood exams were performed to analyse CD4+ T-cell count, HIV viral load and 
peripheral T-lymphocytes immune phenotypes (CD38+CD8+). During gynaecological 
and surgical examinations cervical and anal specimens were collected for cytological 
assessment and detection of HPV infection through HPV-DNA genotyping. 
 
Cervical/anal cytology and HPV detection 
Anal and cervical samples were collected using a Dacron swab to perform a pap 
smear. The cytologic smears were evaluated by expert cyto-pathologists belonging 
to the Pathology Department of San Paolo Hospital, and classified according to the 
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2001 Bethesda System terminology as negative, atypical squamous cells of 
undetermined significance (ASC-US), low-grade squamous intraepithelial lesion 
(LSIL), high-grade intraepithelial lesion (HSIL), or squamous cell carcinoma105.ASC-US 
was considered as a form of LSIL and, in the statistical analysis, patients belonging to 
the two classes were grouped together. 
Specimens from the cervical and anal mucosae were also collected in liquid-based 
cytology medium (PreservCytologic) for HPV-DNA assessment. HPV-DNA was 
detected with PCR using both the L1 consensus primers MY09/MY11 and the E6/E7 
consensus primers PU-1M/PU-2R. Viral genotyping was performed using a direct 
sequencing kit (BD Terminator Kit v 1.1, Applied Biosystems, Life Technologies) on 
an automated capillary electrophoresis sequencer (ABI3130, Applied Biosystems, 
Life Technologies). The oncogenic risk of the different viral genotypes was defined 
according to the epidemiologic classification by Muñozet al.12 
 
T-Lymphocyte Immunophenotype 
Lymphocyte subsets were evaluated by flow cytometric analysis, using 50 μl 
ethylenediaminetetraacetic acid (EDTA) peripheral blood incubated for 30 min at 
4°C with fluorochrome-labeled monoclonal antibodies (mAbs) (CD4, CD8, CD38, 
CD127). After incubation, erythrocyte lysis and fixation of marked cells were 
performed using the Immuno-Prep EPICS kit and Q-prep Work Station (Coulter 
Electronics, Hialeah, FL, USA). 
 
Clinical variables 
At baseline demographic (sex, age and sexual behaviour), clinical (HPV infection at 
anal/cervical site and HPV genotype), immunological (total number and percentage 
of CD4+, CD8+, CD38+CD8+ T-cell) and HIV-related characteristics (time from HIV 
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diagnosis, CDC classification, ongoing cART regimen and duration, current HIV viral 
load, nadir and current CD4+ T-cells) were recorded. 
According to ano-genital HPV infection, patients were defined as HPV-positive 
(HPV+) or HPV-negative (HPV-).  
In the longitudinal study, patients with HPV persistence were defined as the subjects 
HPV-positive at baseline (T0) who remained HPV-positive at follow up (T1) and were 
compared to patients who cleared HPV infection (HPV-positive at T0 who become 
HPV-negative at T1). Histological progression was defined as evolution to a higher 
grade of dysplasia or development of cancer, while histological regression was 
defined as reversion to a lower grade of dysplasia or normalization of anal/ cervical 
cytology.  
 
Statistical analysis 
Data were presented as absolute numbers, percentages and median, interquartile 
range (IQR) for categorical and quantitative variables, respectively. Comparisons 
between HPV-positive versus HPV-negative patients and between patients with SIL 
versus patients with negative cytology, according to gender, were assessed by Chi-
square test for nominal variables and non parametric Mann-Whitney test for 
continuous variables. Multivariate logistic regression models were performed to 
analyse factors independently associated with HPV infection and presence of SIL, 
according to gender. To explore eventual associations between cART exposure and 
HPV infection or SIL, we performed the same analyses  in the group of cART-treated 
patients. 
Analyses were conducted using SPSS (SPSS, version 21.0). 
 
Results 
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A total of 472 patients were consecutively enrolled, 327 (69%) men and 145 (31%) 
women. Cytology and HPV-DNA were available at baseline for all the patients. Main 
characteristics of the study population according to sex are shown in Table 5. 
Males and females were comparable for median age, current CD4+ T cells count at 
the time of enrollment and percentage of patients with AIDS-defining events; 
females were most frequently HIV-infected through heterosexual contacts (96/145, 
66%) and IDU (36/145, 25%), while males where mostly MSMs (254/327, 78%). Not 
surprisingly, syphilis was more frequent in the males group and HCV co-infection 
amongst females reflecting a higher percentage of IDUs.  
Women showed a more advanced HIV-infection as they presented a longer duration 
of HIV infection and a lower nadir of CD4+ T-cells compared to men.  
Women were also more frequently on cART, with a longer duration of median cART 
exposure  and more frequently on a PI-based regimen as compared to men. 
 
Prevalence of HPV infection at baseline 
The global prevalence of HPV infection in our cohort was 74% (350/472 
patients).71/145 (49%) women and 279/327 (85%) males were HPV positive at 
baseline (p<0.001). 
42 out of the 71 (59%) HPV positive women and 223 out of 279 (80%) HPV positive 
men harbored high-risk (HR) genotypes (p=0.001).The most represented HR HPV 
genotypes were HPV 16 (93/265 pts, 35%), HPV 58 (70/265 pts, 26%), HPV 31 
(50/265 pts, 19%) and HPV 18 (46/265 pts, 7%); the distribution of HR and low-risk 
(LR) HPV genotypes is shown in Figure 4. 
22/145 (31%) women and 141/279 (50%) men displayed multiple genotypes 
infection (p=0.008). 
To  investigate the possible role of cART on HPV infection, we compared patients on 
cART (353/472, 75%) with and without HPV infection. Interestingly, HPV positive 
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patients showed shorter exposure to antiretroviral therapy compared to the HPV-
negative ones (median, IQR: 36, 10 – 108 months vs 57, 26-130months;  p=0.01).  
68/353 patients (20%) showed detectable plasma viral load (HIV-RNA >50 cp/ml). 
HPV infection was associated with incomplete viral control (HPV+ patients with HIV-
RNA>50 cp/ml: 56, 22% vs. HPV- patients with HIV-RNA> 50 cp/ml:12, 11% p=0.03). 
In the multivariate logistic regression model, after adjusting for nadir CD4+, duration 
of HIV infection, being MSM and duration of cART, detectable HIV-RNA was 
confirmed as independent predictor of HPV infection in cART-treated patients (AOR 
2.68 vs undetectable patients, 95% CI 1.04-6.88,p=0.04).  
 
Factors associated with HPV infection according to gender 
By examining the study population separately according to gender (Table 6a),we 
observed that among females HPV infection was associated with higher HIV-RNA 
levels whereas there was no correlation with cART status (HPV positive pts on cART 
67/71, 94% vs HPV negative pts on cART 66/74, 89% p=0.26). 
Among males (Table 6a), HPV+ patients  were more frequently MSM and showed a 
shorter time since HIV diagnosis, less AIDS events and higher nadir and current 
CD4+, in comparison to HPV- subjects. HPV+ males were also less frequently on 
cART with a higher proportion of detectable HIV-RNA. In the multivariate analysis, 
MSM (AOR: 3.8 95%CI 1.818-7.946, p=0.0001), lower probability of AIDS(AOR: 0.4 
95% CI:0.176-0.851 p=0.02), and shorter time since HIV diagnosis (AOR: 0.1 95% 
CI:0.992-0.999 p=0.03) were associated with HPV, adjusting for age, CD4+ T cells 
nadir, current CD4+ count, current HIV-RNA and presence of cART. 
 
Cervical and anal cytology at baseline 
224/472 patients (47%) presented normal cervical/anal cytology at baseline; 
218(46%) ASCUS/LSIL and 30 (6%) HSIL.  
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As expected, the presence of ACSUS/LSIL/HSIL was associated with HPV infection 
(SIL: HPV positive patients 221/248, 89% vs HPV negative patients 27/248, 11%; 
p=0.0001), infection with HR-HPV (SIL: HR-HPV 175/248, 72% vs LR-HPV 46/248, 
19% vs HPV negative 27/248 (9%); p=0.0001) and co-infection by multiple HPV 
genotype (SIL: multiple genotypes 126/248, 50% vs single genotype 97/248, 39% vs 
HPV negative 27/248 (9%);p=0.0001). Women were more frequently free from 
intraepithelial lesions (99/145, 68% vs 125/327, 38%,  p<0.001) compared to men 
(Table 1).  
Factors associated with SIL according to gender 
Among women (Table 6b), lower CD4+ count and higher HIV-RNA were associated 
with SIL. We found no differences in age, risk factors, time since HIV diagnosis, AIDS 
events, CD4+ nadir and cART between SIL-positive and SIL-negative females. In the 
multivariate model, lower CD4+ T-cells count was confirmed as an independent 
predictor of intraepithelial lesions (AOR: 0.1; 95%CI: 0.1-1, p=0.05) adjusting for 
current HIV-RNA. 
In the males group (Table 6b) patients with SIL were younger, more frequently 
MSM, with a shorter duration of HIV infection and a higher nadir CD4+ T-cells count 
compared to patients with a normal cytology. Further, males with intraepithelial 
lesions were less likely to be cART-exposed compared to SIL-negative ones, and they 
showed higher Log10 HIV-RNA; the proportion of activated CD38+CD8+ T-cells was 
also higher in SIL-positive patients. When we entered the variables in the 
multivariate model, only younger age was confirmed as a predictor of precancerous 
lesion in males (AOR 0.1, 95% CI 0.9-0,1 p=0.003 every year more) adjusting for 
MSM, time since HIV diagnosis, cART, logVL, CD4+ nadir, CD8+CD38+. 
We then analyzed males on cART and found that men presenting with SIL were 
cART-exposed for a shorter time (p<0.001) compared to men with a normal 
cytology. In the multivariate model, shorter duration of cART (AOR 0.1, 95%CI 0.979-
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0.994 every month more) was an independent predictor of SIL, adjusting for nadir 
CD4+ count, current HIV-RNA and MSM.  
 
Factors associated with HPV clearance 
155/472 patients underwent at least a second gynecological/surgical evaluation 
with cervical/anal sampling, after a median of 19 (IQR 13-30) months.  A total of 30 
patients (19%) cleared HPV: 16 women (52%) and 14 males (11%)(p<0.001) 
(clearance group),whereas 125 (81%) patients showed persistence of HPV infection 
(persistence group)(Table 7). 
Patients in the persistence group harbored more frequently HR-HPV genotypes 
(p<0.001) and were more frequently co-infected with multiple HPV genotypes 
(p=0.001) compared with patients in the clearance group. In the univariate analysis, 
female sex, longer time since HIV diagnosis and being on cART with less frequently 
detectable HIV-RNA and lower levels of CD8+/CD38+% T-cells were associated with 
the capability to clear HPV infection.  
Among males, HPV clearance was associated with longer exposure to cART (Median, 
IQR: 73 months, 31-177 vs 31 months, 11-19 p=0.04) and lower levels of immune 
activation (CD38+CD8+% median, IQR;  1%, 1-2 vs 3%, 1-6 p=0.01).Unlike males, in 
women we observed that a shorter cART exposure (clearance: 35, 6-109 vs 
persistence: 117, 37-178; p=0.03) was associated with HPV clearance.  
 
Factors associated with the progression of dysplastic lesions 
190/472 patient had a cytological evaluation at follow up visit. 112 patients (77%) 
showed SIL persistence with a stable grade of dysplasia, or a stable negative 
cytology, 46 (23%) showed a regression to a lower grade of dysplasia and 32 (16%) a 
progression towards a higher grade of dysplasia (Figure 5). 
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Male sex was associated with changes in the cytological status, both in terms of 
progression and regression of dysplasia, while females were more likely to maintain 
a stable cytology:  in comparison with no modification of cytology, men more 
commonly than females displayed progression of SIL (males: 29/32 pts, 90% vs 
females: 3/32 pts, 9% p=0.01) and were also characterized by higher prevalence of 
regression to lower grade of dysplasia, with a trend towards statistical significance 
(males: 38/46 pts, 83% vs females: 8/46 pts, 17% p=0.07). Patients with progression 
of dysplasia were more frequently MSMs (23/32, 72%) compared to patients with 
stable cytology (62/122, 55% p=0.038) and had a more recent HIV diagnosis (40 
months (19-115) vs 67 months (20-180) p=0.037). 
We further analyzed factors associated with changes in cytological status in the 
males group and we found that males who showed a regression to a lower grade 
dysplasia presented lower levels of CD8+ T-cell activation at baseline compared with 
patients with cytological stability (CD38+CD8+%, Median, IQR: 2% 1-4 vs 3% 1-7 
p=0.04). Males who progressed towards higher grade dysplasia showed a trend to 
higher nadir CD4+ T-cells count compared to patients who remained stable 
(progression: 369 cells/mmc, 271-537 vs no modification: 325 cells/mmc, 202-
427,p=0.05). 
 
Discussion 
In our study cohort, we describe prevalence rates of HPV infection at cervical/anal 
site that overpass those reported for HIV-negative women and men, underlying the 
increased risk to acquire HPV and to develop precancerous lesions and potentially 
invasive cancer in people living with HIV99 106 107 108. Our data, together with well 
consolidated epidemiological evidences, indicates the need for a strong public 
health campaign aimed at widening the HPV vaccination coverage in this population.  
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We also found a significantly higher prevalence of HPV infection in men compared 
to women, and detection of HR-HPV and multiple genotypes infection were also 
more frequent in males.  
We might explain such differences both with the higher frequency of risk-taking 
behavior among MSM109 110 111 (i.e. condom-less sex, use of recreational drugs) 
possibly resulting in the exposure to multiple HPV genotypes, and with the 
characteristics of the rectal mucosa per se, undergoing inflammation for sexual 
practices.  
Previous reports underlined the association of  low CD4+ T-cell counts and increased 
HIV loads with the incidence of cervical HPV infections, as well as with the risk of 
progression of cervical SIL.112 113 114Among  women of our cohort, higher plasma HIV-
RNA was an independent predictor of HPV infection, whereas none of the other HIV-
related or demographic factors yielded significant association. Therefore, 
uncontrolled HIV infection itself seems to lead to an increased susceptibility to HPV 
infection, probably by altering local immunity and tight junctions function. It could 
also be hypothesized that high HIV viral load while on antiretroviral therapy, 
underlying lower adherence,  could be also linked to risky sexual behavior and 
ultimately to higher probability of getting infected by HPV.  
Previous studies conducted in HIV-positive males demonstrated an association 
between impaired immunity as measured by current and nadir CD4+ T-cells count; 
conversely, other authors found a positive association between higher CD4+T-cells 
levels and detection of HPV at anal site115. We showed that HPV-positive males were 
more recently HIV-infected, presented less AIDS events and higher current and nadir 
CD4+ versus HPV-uninfected patients. As expected, they also showed a shorter 
duration of cART exposure.  
 These findings suggest that men, and particularly MSM, are highly prone to HPV 
infection despite a recently acquired HIV-infection and a preserved immune CD4+ 
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count, identifying  behavioral attitudes as more relevant in the risk of HPV 
acquisition than CD4+ depletion in HIV+ men. 
As males were more frequently HPV-infected compared to women, they also 
showed a higher prevalence of precancerous lesions at enrollment, and the 
presence of dysplasia was independently associated with younger age, which is in 
line with previous reports114.  
Moreover, in our cohort, higher T-cell activation rather than current CD4+ count 
appeared to directly influence the presence of SIL in males. The higher prevalence of 
intraepithelial lesions in patients with an activated lymphocytes profile suggests that 
HIV-driven immune de-regulation, by leading to an inadequate protection against 
the oncogenic action of HPV, could promote the development of precancerous 
lesions despite inadequate CD4+ recovery.  
Further, we found that men with SIL were less likely to be cART exposed compared 
with men with a normal cytology, and among those on cART the duration of 
treatment-exposure was shorter; these data point towards a protective role of a 
prompt introduction of cART to prevent precancerous lesion, which is consistent 
with the capability of cART to control, even though not completely, the peripheral 
immune-activation116 117.  
We further evidenced that, besides favoring HPV infection, history of homosexual 
intercourses was also a risk factor for precancerous lesions, underlying the 
importance of screening for behavioral factors.  
Among women, in contrast, the presence of SIL was associated with higher Log10 
HIV-RNA, lower CD4+ T-cells levels and lower CD8+ T-cells percentage; lower CD4+ 
T-cells count was further confirmed as an independent predictor of intraepithelial 
lesions, providing evidence that HPV-mediated  oncogenic modifications in women 
are largely driven by immune suppression.  
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In the longitudinal analysis, we showed that men presented significantly lower rate 
of HPV clearance compared with women, being more likely to maintain a persistent 
HPV infection. In the female group, a shorter duration of antiretroviral therapy was 
the only factor associated with the capability to clear the HPV infection, but our data 
might be inconclusive possibly due to the small numbers of patients. On the other 
hand, higher levels of peripheral immune activation markers were associated with 
both HPV persistence and SIL progression among men, whereas those men who had 
been able to clear HPV presented longer exposure to cART compared with those 
who did not clear the virus. Taken together, these data confirm the importance of 
immune activation in promoting  HPV persistence and carcinogenesis and the role of 
cART in improving HPV clearance.  
 
Our study has several limitations. A major one is that we can’t rule out possible 
confounding due to the difference in epithelial cells type at the cervical and anal 
sample site102; studies assessing HPV detection and clearance by multi-sites 
sampling are needed to better clarify the natural history of the virus in different 
tissue settings. 
Further limitations are represented by the small number of women in the 
longitudinal cohort and the absence of HIV-related or immunological correlates with 
the outcome of HPV clearance and cytological modifications overtime.  
However, data directly comparing the natural history of HPV in men and women are 
scarce, and in our cohort we confirm the high prevalence of HPV infection observed 
in people living with HIV, especially in males and MSM.  
We found that, despite an adequate immune recovery, HPV infection and clearance 
as well as the presence of intraepithelial lesions is largely influenced by risky 
behaviors and persistent immune activation in males, particularly in recently HIV-
infected patients. Among women, on the other hand, the risk of precancerous 
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lesions is linked to immune-suppression as measured by CD4+T-cells count; we 
suggest that these groups of patients should be considered for more accurate 
screening. 
We think that further longitudinal, long-term follow up studies are required to 
better investigate the role of cART in the natural history of HPV infection and in the 
progression of cytological abnormalities. Further, HPV vaccination has to be strongly 
recommended to all HIV positive men and women, independently form the age. 
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Table 1. Characteristics of study population at the time of cancer diagnosis.  
 
Characteristics of study 
population 
Virus-related cancers  
(115) 
Non virus-related cancers 
(25) 
P value 
Male sex° 99 (86) 15 (60) 0.002 
Age(years) * 44 (36-51) 56 (48-61) <0.001 
Homosexuals ° 
Heterosexuals 
IDUs 
62 (53) 
25 (22) 
28 (24) 
 
7 (28) 
14 (56) 
4 (16) 
 
0.003 
AIDS diseases ° 81 (73%) 18 (72%) 0.55 
Months since HIV diagnosis * 48 (0.25-158) 144 (26-239) 0.04 
HCVAb positive ° 
 
40 (35) 10 (40) 0.66 
cART° 57 (51) 20 (80) 0.007 
Log10 HIV-RNA (cp/ml)* 3.43 (1.62-4.84) 1.69 (1.59-4.8) 0.128 
Nadir CD4+ (cells/mmc)* 118 (49-265) 135 (71-210) 0.97 
CD4+ (cells/mmc)* 219 (112-481) 400 (305-563) 0.004 
CD8+ (cells/mmc)* 818 (563-1162) 861 (569-1310) 0.54 
CD4+/CD8+ ratio* 0.33 (0.14-0.60) 0.54 (0.34-0.73) 0.01 
CD8+CD38+ (cells/mmc)* 137 (76-315) 95 (45-849) 0.99 
CD8+CD38+ (%)* 
6 (3-17) 4 (1.5-6) 0.088 
*Data are presented as the median (IQR). °Data are presented as absolute numbers (%). P values for comparison 
between virus-related and non-virus related cancer  
Abbreviations: IDUs: injection drug users; cART: combination antiretroviral therapy 
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Table 1. Factors associated with virus-related and non virus-related cancers in cART-treated patients 
Characteristics  of population 
(N=77) 
Virus-related cancers 
(n=57) 
Non virus-related 
cancers 
(n=20) 
P value 
Male sex°  45 (79)  12 (60)  0.09 
Age(years) *  48 (40-52)  57 (51-65)  <0.001  
Homosexuals °  
Heterosexuals  
IDUs  
21  
13  
23  
6  
10 
4  
0.06  
AIDS diseases °  18 (31)  7 (35)  0.51  
Months since HIV diagnosis *  138 (29-229)  163 (51-256)  0.38  
HCVAb positive °  32  7  0.19  
HIV-RNA <40 cp/ml  33 (58)  15 (75)  0.21 
Months on cART* 59 (19-186) 180 (81-239) 0.01 
Nadir CD4+ (cells/mmc)*  118 (49-225)  128 (84-209)  0.93  
CD4+ (cells/mmc)*  280 (152-556)  414 (305-608)  0.025  
CD8+ (cells/mmc)*  756 (326-1146)  861 (569-1310)  0.28  
CD4+/CD8+ ratio*  0.47 (0.25-0.71)  0.59 (0.38-0.83)  0.21  
CD8+CD38+ (Cells/mmc)*  
88 (49-137)  86 (39-606)  0.73  
CD8+CD38* (%)*  
4 (2-6) 2.5 (1-6)  0.24  
*Data are presented as the median (IQR). °Data are presented as absolute numbers (%). P values for comparison 
between virus-related and non-virus related cancer in patients on cART. 
Abbreviations: IDUs: injection drug users; cART: combination antiretroviral therapy.  
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Figure 1. Kaplan Meier overall survival curve for patients with virus-related and non-virus related cancer  
 
 
(Logrank p=0.004) 
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Table 3. Clinicopathological features of 157 patients with HIV associated DLBCL 
  
Male gender° 131/157 (83%) 
Mean age at DLBCL diagnosis (range)* 45 years (19-75) 
Prior AIDS defining illness° 31/157 (20%) 
On cART at DLBCL diagnosis° 97/157 (62%) 
Plasma HIV VL undetectable on cART at DLBCL diagnosis° 56/97 (58%)  
Stage° I: 19/157 (12%) 
II:12/157 (8%) 
III: 11/157 (7%) 
IV: 115/157 (73%) 
ECOG PS° 0: 11/156 (7%) 
1: 67/156 (43%) 
2: 28/156 (18%) 
3: 23/156 (15%) 
4: 27/156 (17%) 
IPI° Age>60: 16/157 (10%) 
PS>1: 79/156 (51%) 
Raised LDH: 101/155 (65%) 
Stage>2: 126/157 (80%) 
>1 extranodal site: 70/155 (45%) 
IPI group L: 38/155 (25%) 
LI: 35/155 (23%) 
HI: 38/155 (25%) 
H: 44/155 (28%) 
*Data are presented as the median (IQR). °Data are presented as absolute numbers (%).  
Abbreviations : DLBCL: diffuse large B-cell lymphoma; cART: combination antiretroviral therapy; ECOG PS:  Eastern 
Cooperative Oncology Group (ECOG) performance status; IPI: International Prognostic Index  
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Table 4. Immunological parameters at lymphoma diagnosis by histology  
 All 
(n=361) 
NHL 
(n=271) 
DLBCL 
(n=157) 
BL  
(n=62) 
PBL 
(n=17) 
PEL 
(n=18) 
PCL  
(n=17) 
HD 
(n=90) 
Kruskal-
Wallis 
CD56+ (IQR) 
cells/mm3 
64  
(92) 
64  
(89) 
63  
(80) 
69  
(76) 
69 
(125) 
58 
(89) 
24 
(74) 
74  
(117) 
p=0.10 
CD56+ % 
(IQR) 
6.0 % 
(8.0) 
6.0% 
(8.0) 
6.3%  
(7.7) 
5.0(8.0) 5.0%  
(5.2) 
3.2%  
(6.0) 
5.5%  
(6.2) 
9.0%  
(8.0) 
p=0.0092 
CD4+ (IQR) 
cells/mm3 
216  
(282) 
115 
(253) 
153  
(289) 
221 
(231) 
253 
(253) 
216 
(300) 
79 
(331) 
271 
(317) 
p=0.010 
CD4+ % 
(IQR) 
17% 
(16) 
15% 
(15) 
15%  
(16) 
13%  
(8.0) 
20%  
(16) 
14% 
(12) 
12%  
(20) 
24%  
(15) 
p<0.0001 
CD8+ (IQR) 
cells/mm3 
566  
(613) 
591 
(642) 
560 
(526) 
854 
(1039) 
837 
(1000) 
822 
(902) 
406  
(608) 
515  
(546) 
p=0.0006 
CD8+ % 
(IQR) 
55% 
(21) 
57% 
(22) 
51%  
(21) 
58%  
(20) 
52%  
(20) 
58%  
(24) 
54%  
(24) 
51%  
(19) 
p=0.166 
CD19+ (IQR) 
cells/mm3 
103  
(132) 
115 
(145) 
93  
(127) 
158 
(216) 
225  
(142) 
121  
(97) 
113  
(151) 
58  
(93) 
p<0.0001 
CD19+ % 
(IQR) 
8% 
(10) 
9.7% 
(12) 
8.5%  
(8.7) 
11% 
(12) 
18%  
(13) 
9.0% 
(12) 
14%  
(13) 
5.5%  
(6.0) 
p<0.0001 
 
Data are presented as median and interquartile ranges (IQR). 
Abbreviations: DLBCL= diffuse large B-cell lymphoma; BL= Burkitt lymphoma; PBL=plasmablastic lymphoma; PEL= 
primary effusion lymphoma; PL= primary cerebral lymphoma 
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Figure 2. CD56+ count at lymphoma diagnosis for all hisologies 
 
 
Figure 2A. Bivariate scattergram of CD4+ and CD56+ at lymphoma diagnosis for all histologies (n=360)   
(Bartlett’s test of sphericity p<0.0001). 
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Figure 2B. CD56+ count at lymphoma diagnosis for all histologies (n=360) by HIV virological status.  
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Figure 3. Kaplan Meier overall survival curve for 149 patients with HIV associated DLBCL treated with 
combination chemotherapy with curative intent 
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Table 5. DLBCL treated with curative chemotherapy (n=149) 
  
Male gender° 123/149 (83%) 
Mean age at DLBCL diagnosis (range)* 45 years (19-75) 
Prior AIDS defining illness° 27/149 (18%) 
On cART at DLBCL diagnosis° 91/149 (61%) 
Plasma HIV VL undetectable on cART at DLBCL diagnosis° 53/91 (58%)  
Stage° I: 18/149 (12%) 
II: 12/149 (8%) 
III: 11/149 (7%) 
IV: 108/149 (72%) 
ECOG PS° 0: 10/149 (7%) 
1: 66/149 (44%) 
2: 27/149 (18%) 
3: 22/149 (15%) 
4: 24/149 (16%) 
IPI° Age>60: 15/149 (10%) 
PS>1: 74/149 (50%) 
Raised LDH: 97/149 (65%) 
Stage>2: 119/149 (80%) 
>1 extranodal site: 66/149 (44%) 
IPI group° L: 37/149 (25%) 
LI: 34/149 (23%) 
HI: 37/149 (25%) 
H: 41/149 (28%) 
Chemotherapy° R-CHOP: 84/149 (56%) 
CDE: 63/149 (42%) 
R-CODOX-M/IVAC: 2/149 (2%) 
Relapsed° 29/149 (19%) 
Dead° 50/149 (34%) 
Survival* 2 year OS: 70% (95%CI: 62-78%) 
5 year OS: 66% (95%CI: 58-74%) 
10 year OS:  (95%CI: 52-71%) 
*Data are presented as the median (IQR). °Data are presented as absolute numbers (%).  
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Legend: DLBCL: diffuse large B-cell lymphoma; cART: combination antiretroviral therapy; ECOG PS:  Eastern Cooperative Oncology 
Group (ECOG) performance status; IPI: International Prognostic Index 
 
                                  Figure 4. Prevalence of different HPV genotypes (n=350/472, 74%)  
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Table 5. Characteristics of the study population according to gender 
Baseline parametres Population (n=472) Males (n=327) Females (n=145) p 
Age (years) * 41 (34-47) 40 (33-46) 43 (39-48) 0.066 
Homosexuals° 
Heterosexuals 
IDUs 
Other/not known 
254 (54%) 
144 (30%) 
58 (12%) 
16 (4%) 
254 (77.7%) 
48 (14.7%) 
22 (6.7%) 
3 (0.9%) 
- 
96 (66.2%) 
36 (24.8%) 
13 (9%) 
0.0001 
Months since HIV diagnosis*  49 (14-144) 34 (8-100) 144 (48-222) 0.0001 
AIDS diseases°  84 (18%) 54 (17%) 30 (23%) 
0.113 
HCV Ab positive° 
HCV Ab negative 
Not known 
60 (13%) 
403 (85%) 
9 (2%) 
32 (10%) 
289 (88%) 
6 (2%) 
28 (19%) 
114 (79%) 
3 (2%) 
0.016 
cART ° 353 (75%) 220 (67%) 133 (92%) 0.0001 
PI–based cART° 
NNRTI-based cART 
INSTI-based cART 
Others 
129 (36%) 
170 (48%) 
53 (15%) 
1 (1%) 
62 (28%) 
113 (51.6%) 
44 (20%) 
1  (0.4%) 
67 (50%) 
57 (43%) 
9 (7%) 
0  
0.0001 
Months on cART * 43.5 (14-110) 32 (8.25-90.7) 72 (31.5-134.2) 
0.01 
Nadir CD4+ T cells (cells/mmc)* 285 (164-432) 322 (191-480) 203 (105-288) 0.0001 
CD4+ T cells (cells/mmc)* 504 (368-660) 512 (394-664) 477 (337-659) 0.364 
CD4+% * 27 (21-32) 27 (21-32) 31 (20-38) 0.753 
CD8+% * 48 (40-57) 48 (40-56) 47 (38-59) 0.312 
CD127+CD4+% * 15 (10-21) 15 (10-20) 17 (12-23) 0.421 
CD127+CD8+% * 19 (12-27) 20 (12-28) 17 (12-25) 
0.215 
CD38+CD8+% * 3 (1-7) 3 (1-7) 2 (1-5) 0.067 
Log10 HIV-RNA (cp/mL)* 1.73 (1.59-3.33) 1.77 (1.59-3.9) 1.59 (1.59-1.79) 0.0001 
HIV-RNA > 50 cp/mL° 
177 (37%) 146 (45%) 31 (21%) 0.0001 
HPV negative ° 
HPV positive 
HPV HR genotypes 
HPV LR genotypes 
Not known genotype 
122 (26%) 
350 (74%) 
265 (56%) 
82 (18%) 
3 (1%) 
48 (15%) 
279 (85%) 
223 (68%) 
55 (16.8%) 
1 (0.2%) 
74 (51%) 
71 (49%) 
42 (29%) 
27 (19%) 
2 (1%) 
0.0001 
Multiple HPV genotypes ° 
163 (46%) 141 (50%) 22 (31%) 0.008 
Negative cytology ° 
LSIL 
HSIL 
224 (47.4%) 
218 (46.2%) 
30 (6.4%) 
125 (38%) 
179 (55%) 
23 (7%) 
99 (68.3%) 
39 (26.9%) 
7 (5%) 
0.0001 
 
*Data are presented as the median (IQR). °Data are presented as absolute numbers (%). P values for comparison between males 
and females. 
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Abbreviations: IDUs: injection drug users; cART: combination antiretroviral therapy; PI: Protease Inhibitor; NNRTI: Non-Nucleoside 
Reverse Transcriptase Inhibitor; INSTI: Integrase Strand Transfer Inhibitors; HPV: Human Papilloma virus; HPV HR genotypes: 
Human Papilloma Virus High-risk genotypes; HPV LR genotypes: Human Papilloma Virus Low-risk genotypes; LSIL: low-grade 
squamous intraepithelial lesion; HSIL: high-grade intraepithelial lesion.  
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Table 6. Factors associated with HPV infection (a) and with SIL (b) in females and males 
Table 6a. Factors associated with HPV infection    
 Females (N 145)    
Characteristics HPV negative (N 74) HPV positive (N 71) p 
Log10 HIV-RNA (cp/mL)* 1.59 (1.59-1.75) 1.77 (1.59-2.03) 0.002 
HIV-RNA >50 cp/mL° 12 (16%) 19 (27%) 0.146 
SIL ° 9 (12%) 36 (51%) 0.0001 
 
 Males (N 327) 
Characteristics HPV negative (N 48) HPV positive (N 279) p 
Months since HIV diagnosis * 73 (18-144) 31 (7-85) 0.002 
Homosexuals ° 
Heterosexuals 
IDUs 
Other/notknown 
24 (50%) 
9 (19%) 
13 (27%) 
2 (4%) 
230(82%) 
39 (14%) 
9 (3%) 
1 (0.3%) 
0.0001 
AIDS diseases ° 17 (35%) 37 (13%) 0.0001 
HCV Ab positive ° 
HCV Ab negative 
Not known 
10 (21%) 
36 (75%) 
2 (4%) 
22 (7.8%) 
253 (90%) 
4 (1%) 
0.007 
HBsAg positive ° 
HBsAg negative 
Not known 
17 (35%) 
30 (63%) 
1 (2%) 
53 (19%) 
221 (79%) 
5 (2%) 
0.036 
cART° 38 (79%) 182 (65%) 0.057 
Months on cART* 47  (23-132) 29  (7-84) 0.039 
Log10 HIV-RNA (cp/mL)* 1.59 (1.59-2.52) 1.77 (1.59-4.09) 0.006 
HIV-RNA >50 cp/mL° 14 (29%) 132 (47%) 0.024 
Nadir CD4+ (cell/mmc)* 214 ( 117-3158) 335 (200-484) 0.004 
CD4+ (cell/mmc) * 444 (358-581) 519 (402-681) 0.026 
HPV HR genotypes ° 
HPV LR genotypes 
Not known genotype 
- 
- 
223 (79.9%) 
55 (19.7%) 
1 (0.4%) 
 
Multiple HPV genotypes ° - 141 (50%)  
SIL 14 (29%) 188 (67%) 0.0001 
 
Table 6b. Factors associated with SIL 
 Females (N 145)  
Characteristics SIL negative (N 99) SIL positive (N 46) p 
Log10 HIV-RNA (cp/mL)* 1.59 (1.59-3.17) 1.77 (1.59-1.94) 0.024 
HIV-RNA >50 cp/mL° 19 (19%) 12 (26%) 0.488 
CD4+ (cell/mmc) * 525 (368-687) 420 (305-598) 0.033 
CD4+% * 34 (25-40) 21 (14-28) 0.033 
CD8+% * 40 (36-56) 51 (49-63) 0.017 
HPV negative ° 
HR HPV genotypes 
LR HPV genotypes 
64 (66%) 
19 (20%) 
14 (14%) 
10 (22%) 
23 (50%) 
13 (28%) 
0.0001 
Males (N 327)    
Characteristics SIL negative (N 125) SIL positive (N 202) p 
Age (years) * 42 (34-47) 39 (33-45) 0.026 
Months since HIV  
diagnosis * 
46(11-123) 31 (7-85) 0.035 
Homosexuals ° 
Heterosexuals 
IDUs 
Other/notknown 
85 (68%) 
25 (20%) 
12 (10%) 
3 (2%) 
167 (83%) 
23 (11%) 
10 (5%) 
2 (1%) 
0.044 
HBsAg positive ° 
HBsAg negative 
Not known 
34 (27%) 
91 (73%) 
0 
36 (18%) 
160 (79%) 
6 (3%) 
0.026 
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cART ° 92 (74%) 128 (64%) 0.055 
Months on cART * 44 (22-121) 23 (5-62) 0.0001 
Log10 HIV-RNA (cp/mL)* 1.59 (1.59-3.17) 2 (1.59-4.08) 0.031 
HIV-RNA >50 cp/mL° 45 (36%) 101 (50%) 0.009 
Nadir CD4+ (cell/mmc)* 279 (154-449) 342 (213-492) 0.039 
CD127+CD8+% * 18 (10-25) 22 (14-30) 0.0001 
CD38+CD8+% * 2 (1-7) 3 (2-9) 0.013 
HPV negative ° 
HR genotypes 
LR genotypes 
35 (28%) 
68 (54%) 
22 (18%) 
14 (69%) 
155 (77%) 
33 (16%) 
0.0001 
Multiple HPV genotypes ° 29/90 (32%) 112/188 (59%) 0.0001 
 
*Data are presented as the median (IQR). Mann Whitney test. °Data are presented as absolute numbers (%). Chi-square test. P 
values for comparison between HPV  negative and HPV positive and between SIL negative and SIL negative patients.  
Abbreviations: SIL: squamous intraepithelial lesion; IDUs: injection drug users; cART: combination antiretroviral therapy; HPV: 
Human Papilloma Virus; HPV HR genotypes: Human Papilloma Virus High-risk genotypes; HPV LR genotypes: Human Papilloma 
Virus Low-risk genotypes 
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Table 7. Factors associated with clearance of HPV infection  
Characteristics HPV persistence (n 125) HPV Clearance (n 30) p 
Age, years* 41 (34-46) 41 (38-49) 0.155 
Male° 110 (88%) 14 (47%) 0.0001 
Months since HIV diagnosis* 41 (18-142) 113 (42-186) 0.007 
Homosexual epidemiology° 
Heterosexual epidemiology° 
IDUs° 
Other/not known° 
95 (76%) 
21 (16.8%) 
8 (6.4%) 
1 (0.8%) 
10 (33%) 
14 (47%) 
6 (20%) 
0 
0.0001 
Previous AIDS diseases° 10 (8%) 5 (20%) 0.117 
HCV positive° 11 (8%) 5 (17%) 0.203 
HCV negative° 114 (91%) 25 (83%) 
HCV unknown° 0 0 
HBSAg pos° 28 (22.4%) 9 (30%) 0.615 
HBsAg neg° 96 (76.8%) 21(70%) 
HBV unknown° 1 (0.8%) 0 
On cART° 85 (68%) 26 (90%) 0.019 
cART duration* 57 (26-130) 56 (22-111) 0.495 
Log10 cp/mL HIV RNA* 1.77 (1.59-4.25) 1.77 (1.59-1.77) 0.052 
CD4+ T cell nadir, cell/mmc* 322 (180-448) 270 (143-394) 0.25 
CD4+ T cells count, cell/mmc* 516 (378-714) 448 (337-560) 0.162 
CD4+ T cells %* 28 (21-34) 32 (23-34) 0.181 
CD8+%* 45 (39-56) 45 (38-53) 0.464 
CD127+CD4+%* 16 (10-22) 17 (11-23) 0.246 
CD127+CD8+%* 15 (10-23) 14 (10-21) 0.741 
CD38+CD8+%* 3 (1-6) 1 (1-3) 0.003 
HR HPV genotypes° 105 (84%) 15 (50%) 0.0001 
LR HPV° 20 (16%) 15 (50%) 
Multiple HPV genotypes° 72 (57%) 12g (41%) 0.001 
SIL° 87 (70%) 12 (40%) 0.002 
 
*Data are presented as the median (IQR). Mann Whitney test. °Data are presented as absolute numbers (%). Chi-
square test. P values for comparison between patients who cleared the HPV infection and patients with HPV-infection 
persistence.  
Abbreviations: IDUs: injection drug users; cART: combination antiretroviral therapy; HPV: Human Papilloma Virus; HPV 
HR genotypes: Human Papilloma Virus High-risk genotypes; HPV LR genotypes: Human Papilloma Virus Low-risk 
genotypes; SIL: squamous intraepithelial lesion 
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Figure 5. Cytological evaluation at follow up (N=190)
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